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(57) ABSTRACT 
The present invention provides artificial enzymes compris 
ing, e.g., an N-terminal domain derived from E. coli FkpA 
that allows for dimerization and provides a substrate binding 
region, and a C-terminal thioredoxin domain derived from E. 
coli DsbA. Similar to DsbC, such de novo designed chimeric 
(hybrid) FkpA-DsbA enzymes function, as disulfide reduc 
tases, oxidases, or isomerases, and chaperones in Vivo and in 
vitro, despite lacking similarity to DsbC-related polypeptide 
Sequence. 
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1. 
ARTIFICAL DISULFIDE ISOMERASES AND 
USES THEREOF 
The present application claims priority to U.S. patent 
application Ser. No. 60/790,522 filed Apr. 7, 2006, the entire 
text of which is specifically incorporated by reference herein 
without disclaimer. 
This invention was made with government Support under 
grant number GMO55090 awarded by the National Institutes 
of Health. The government has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The invention generally concerns the field of molecular 
biology. More specifically, the invention relates to methods 
and compositions for efficient expression of polypeptides 
comprising disulfide linkages. 
2. Description of Related Art 
Oxidative protein folding involves two complementary but 
competing processes: cysteine thiol oxidation, and isomer 
ization of non-native disulfide bonds. The limiting step in the 
folding of multidisulfide eukaryotic proteins in the bacterial 
periplasm is often the isomerization of non-native disulfides. 
The bacterial disulfide bond formation (“Dsb) protein 
family consists of two distinct pathways, DsbA-DsbB, and 
DsbC/DsbG-DsbD, involved in the formation of disulfides 
and in the rearrangement of incorrectly formed bonds, respec 
tively (Kadokura et al., 2003: Collet and Bardwell, 2002). 
The extreme oxidizing nature of mature DsbA (SEQ ID 
NO:3) mediates rapid oxidation of substrate cysteines, which 
results in the formation of non-native disulfides, in turn rear 
ranged by DsbC. Consequently, despite the strong oxidizing 
environment of the periplasmic space, DsbC has to be main 
tained in a reduced state to interact with the substrate oxidized 
cysteines (Kadokura et al., 2003: Collet and Bardwell, 2002). 
To carry on their catalytic activities, DsbA and DsbC are 
maintained, respectively, in entirely oxidized and reduced 
states (Ramm and Pluckthun, 2001). DsbA is recycled by the 
membrane protein DsbB, whereas DsbC is maintained in the 
reduced state by the membrane protein, DsbD (Arie et al., 
2001). Interactions between the two pathways are strongly 
prevented by kinetic constraints (Rozhkova et al., 2004). As a 
result, the strong thiol oxidant DsbA, and the strong thiol 
reductant DsbC, despite coexisting in the same cellular envi 
ronment, do not appear to exchange electrons with each other, 
but instead act synergistically during oxidative protein fold 
ing. Remarkably, the catalytic domains of DsbC and DsbA 
show a considerable degree of structural homology, and they 
both contain a CXXC thioredoxin active site motif for the 
catalysis of disulfide exchange reactions. 
The folding of at least three native proteins, namely the 
periplasmic acid phosphatase App A or phytase, the pepti 
doglycan amidase Mep A, and RNase I have been shown to 
depend on the presence of DsbC (Berkmen et al., 2005). In 
addition, the folding of a number of heterologous proteins has 
been shown to require overexpression of DsbC (Kadokura et 
al., 2003: Collet and Bardwell, 2002; Kim et al., 2004; 
Kurokawa et al., 2001). It was previously shown that the yield 
of active VtPA, a truncated version of human tissue plasmi 
nogen activator containing 9 disulfide bonds, depends on the 
DsbC expression level (Qiu et al., 1998). 
Zhao et al. (2003) created several engineered polypeptides 
containing an N-terminal DsbC domain joined to a C-termi 
nal domain from thioredoxin (Trx), DsbA, or portions of 
protein-disulfide isomerase (PDI). These polypeptides dis 














retaining DsbC-related sequences. It was suggested that the 
basis of the catalytic activity of DsbC resides in its V-shaped 
dimeric structure, which allows for the formation of a hydro 
phobic substrate binding cleft with chaperone activity, and in 
the presence of two catalytic thioredoxin domains (Segatoriet 
al., 2004). The hybrid DsbC-DsbA or DsbC-TrXA polypep 
tides described in Segatori et al., 2004, in which the catalytic 
domain of DsbC had been replaced with DsbA, also displayed 
disulfide bond formation and isomerase activity, and afforded 
vtPA yields comparable to those obtained when overexpress 
ing wild-type DsbC under the same conditions. However, the 
chimeric proteins of Zhao et al. and Segatorietal. each retain 
DsbC-derived sequences. 
The E. coli periplasm contains two classes of enzymes that 
assist the folding of proteins by catalyzing covalent modifi 
cation: enzymes that catalyze the reduction and oxidation of 
disulfide bonds (the Dsb family), and enzymes that catalyze 
cis/trans peptidyl-prolyl isomerization reactions (PPIases) 
(Baneyx and Mujacic, 2004). Among the PPIases (E.C. 
5.2.1.8), which include SurA (Behrens et al., 2001) and the 
FK506 binding proteins (FKBPs), an FkpA (e.g., GenBank 
L28082) has been recently biochemically characterized,and 
its crystal structure has been solved (Saul et al., 2004). FkpA 
is a homodimeric V-shaped protein (e.g., FIG. 1) which 
exhibits a similar gross topology to DsbC. Each monomer in 
FkpA is formed by an N-terminal dimerization domain and a 
C-terminal catalytic domain, joined by a long C-helical 
linker. The two domains are each structurally and function 
ally independent. The dimerization domains form a binding 
pocket for the interaction with the substrate, and have been 
shown to have chaperone activity (Saul et al., 2004; Ramm 
and Pluckthun, 2001; Arie et al., 2001). FkpA and DsbC lack 
Substantial amino acid sequence identity (e.g., using BLAST 
with default parameters). There exists a need for methods to 
catalyze disulfide bond formation and isomerization in bac 
teria without the expression of a DsbC-containing protein. 
SUMMARY OF THE INVENTION 
The present invention provides, in one embodiment, an 
engineered polypeptide lacking Substantial amino acid 
sequence identity with DsbC that is nonetheless capable of 
catalyzing disulfide bond formation, disulfide bond isomer 
ization, and/or chaperone activity in bacteria. In one aspect, 
the invention provides an isolated nucleic acid molecule 
encoding a chimeric polypeptide comprising a first DNA 
segment encoding an N-terminal domain derived from the 
N-terminal domain of a chaperone that has a V-shaped sub 
strate binding cleft; and a second DNA segment encoding a 
C-terminal domain comprising DsbA or TrxA; wherein the 
first and second DNA segments are linked 5' to 3', and 
wherein the chimeric polypeptide comprises one or more 
activities selected from the group consisting of disulfide bond 
reduction activity, disulfide bond oxidation activity, disulfide 
bond isomerization activity, and chaperone activity. In one 
embodiment, the N-terminal chaperone domain is the N-ter 
minal domain of an FkpA or an FkpA derivative, wherein the 
FkpA derivative allows for dimerization and provides a sub 
strate binding region and has from about 80% to about 99% 
sequence identity with a wild-type FkpA. In a further embodi 
ment, the N-terminal domain comprises residues 1-114 of 
FkpA. In a particular embodiment, the first DNA segment 
encodes a polypeptide comprising SEQID NO:2 or a protein 
fragment of a gene selected from the group consisting of 
GenBank Accession Number AAN44828, GenBank Acces 
sion Number AAL22316, and GenBank Accession Number 
L28082; wherein the protein fragment allows for dimeriza 
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tion and provides a Substrate binding region. The second 
DNA segment may encode a polypeptide comprising DsbA. 
In certain embodiments, the second DNA segment encodes a 
polypeptide comprising SEQID NO:3, GenBank Accession 
Number YP 08.1862, or GenBank Accession Number 5 
U84726. 
In another embodiment, the second DNA segment encodes 
a C-terminal domain comprising a DsbA polypeptide. In yet 
other embodiments, the encoded chimeric polypeptide com 
prises a sequence selected from the group consisting of SEQ 10 
ID NO:4 to SEQ ID NO:8. In various embodiments, the 
chaperone is not DsbC. 
In another aspect, the invention provides an expression 
construct comprising a nucleic acid molecule that encodes a 
chimeric polypeptide comprising a first DNA segment encod- 15 
ing an N-terminal domain derived from the N-terminal 
domain of a chaperone that has a V-shaped substrate binding 
cleft; and a second DNA segment encoding a C-terminal 
domain comprising DsbA, wherein the first and second DNA 
segments are linked 5' to 3', and the chimeric polypeptide 20 
comprises one or more activities selected from the group 
consisting of disulfide bond reduction activity, disulfide bond 
oxidation activity, disulfide bond isomerization activity, and 
chaperone activity; and a DNA segment encoding a polypep 
tide comprising at least two disulfide bonds. In certain 25 
embodiments the nucleic acid molecule that encodes a chi 
meric polypeptide comprises a sequence selected from the 
group consisting of SEQID NO:11-SEQID NO:15. 
In yet another aspect, the invention provides a host cell 
comprising a nucleic acid molecule encoding a chimeric 30 
polypeptide comprising a first DNA segment encoding an 
N-terminal domain derived from the N-terminal domain of a 
chaperone that has a V-shaped Substrate binding cleft; and a 
second DNA segment encoding a C-terminal domain com 
prising DsbA, wherein the first and second DNA segments 35 
are linked 5' to 3', and the chimeric polypeptide comprises one 
or more activities selected from the group consisting of dis 
ulfide bond reduction activity, disulfide bond oxidation activ 
ity, disulfide bond isomerization activity, and chaperone 
activity. In one embodiment, the host cell is a gram negative 40 
or a gram positive bacterial cell. In a particular embodiment, 
the host cell of is a gram-negative bacterial cell, such as an 
Escherichia coli cell. The host cell may express at least one of 
DsbD and DsbB. 
In yet another aspect, the invention provides a method for 45 
producing a biologically active heterologous polypeptide in a 
host cell comprising: a) culturing host cells in a culture 
medium, wherein the host cells comprise both a nucleic acid 
molecule encoding the chimeric polypeptide as described 
above, and a second nucleic acid molecule that encodes a 50 
heterologous polypeptide which comprises at least two dis 
ulfide bonds in its native form; b) expressing the nucleic acid 
molecule and the second nucleic acid molecule in the host 
cells under conditions effective to produce the chimeric 
polypeptide and the heterologous polypeptide; and c) isolat- 55 
ing the heterologous polypeptide. In certain embodiments, 
the heterologous polypeptide is selected from the group con 
sisting of human teA; VtPA, RNAse A, and PhoA. In one 
embodiment of the method, the host cells are bacterial cells. 
In certain embodiments, the bacterial cells express DsbD and 60 
DsbB. In another embodiment, the bacterial cells are gram 
negative bacterial cells. In a particular embodiment, the bac 
terial cells are E. coli cells. In yet another embodiment, at 
least one of the chimeric polypeptide and the heterologous 
polypeptide are operatively linked to a signal sequence that 65 
functions to cause secretion of the polypeptides from the host 
cell cytoplasm. The signal sequence may comprise Omp.A, 
4 
Lpp, LamB, MalE, PelB, or StII. The nucleic acid molecule 
encoding the chimeric polypeptide and the second nucleic 
acid molecule may be expressed by a single host cell or by 
separate host cells. In yet another embodiment of the method, 
the heterologous polypeptide is isolated from the culture 
medium of the host cells. 
The term “effective,” as that term is used in the specifica 
tion and/or claims, means adequate to accomplish a desired, 
expected, or intended result. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
meaning of “one or more.” “at least one and “one or more 
than one.” 
It is contemplated that any embodiment discussed in this 
specification can be implemented with respect to any method 
or composition of the invention, and vice versa. Furthermore, 
compositions of the invention can be used to achieve methods 
of the invention. 
Throughout this application, the term “about is used to 
indicate that a value includes the inherent variation of error 
for the device, the method being employed to determine the 
value, or the variation that exists among the study subjects. 
The use of the term 'or' in the claims is used to mean 
“and/or unless explicitly indicated to refer to alternatives 
only or the alternatives are mutually exclusive, although the 
disclosure Supports a definition that refers to only alternatives 
and “and/or.” 
As used in this specification and claim(s), the words "com 
prising (and any form of comprising. Such as “comprise' and 
“comprises”), “having (and any form of having, such as 
"have and “has”), “including (and any form of including, 
such as “includes and “include’) or “containing (and any 
form of containing, Such as “contains and “contain’) are 
inclusive or open-ended and do not exclude additional, unre 
cited elements or method steps. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indicat 
ing specific embodiments of the invention, are given by way 
of illustration only, since various changes and modifications 
within the spirit and scope of the invention will become 
apparent to those skilled in the art from this detailed descrip 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings are part of the present specifica 
tion and are included to further demonstrate certain aspects of 
the present invention. The invention may be better understood 
by reference to the drawings in combination with the detailed 
description of specific embodiments presented herein. 
FIG. 1 Schematic representation of DsbC, DsbA, and 
FkpA, and domain composition of the FkpA-DsbA chimera 
polypeptides. 
FIG. 2. Disulfide-bond formation in vivo. (A) Yield of 
active vtPA in disbC or dsbA cells and relative expression 
levels of the FkpA-DsbA hybrid polypeptide. PB351 (SF100 
AdsbC), or PB401 (SF100 disbA) transformed with pTrcSti 
IvtPA and pBAD derivatives encoding the respective fusion 
proteins were grown in LB media. Protein synthesis was 
induced as described in the Examples, and the yield of active 
VtPA at 3 hafter induction was determined. Relative activities 
were obtained by dividing the AAaos (absorbance of each 
strain Subtracted of the background consisting of a strain not 
expressing tPA) by the AAaos of a strain expressing VtPA 
US 7,829,687 B2 
5 
alone. (B) PhoA activity. Effect of the expression of the 
chimeric proteins on alkaline phosphatase activity in the peri 
plasm of MC1000 dsbA (white bars) and MC1000 dsbB 
(black bar). The alkaline phosphatase activity of the parental 
isogenic strain MC1000 is shown by the gray bar. Cells were 
induced with 0.2% arabinose, harvested in mid-log phase, 
and lysed, and activity assays were conducted as described in 
Examples 2-4. 
FIG.3. Size-exclusion chromatograms of FkpADsbA2 and 
DsbC. 
DETAILED DESCRIPTION OF THE INVENTION 
The folding of multi-disulfide containing proteins in the 
periplasm of E. coli occurs through the rapid, non-specific 
oxidation of cysteines by DsbA, and is limited by the need for 
Subsequent isomerization of non-native disulfides (Berkmen 
et al., 2005; Zapun et al., 1993). To overcome this limitation, 
the present invention provides, in specific embodiments, arti 
ficial disulfide isomerases that: (1) can catalyze the folding of 
multi-disulfide proteins expressed in bacteria or other organ 
isms and (2) comprise unique amino acid sequences that that 
form proteins not found in any naturally occurring disulfide 
isomerase. 
The present invention describes the construction of artifi 
cial enzymes comprising an N-terminal domain derived from 
FkpA that allows for dimerization and provides a substrate 
binding region, and a C-terminal thioredoxin domain derived 
from DsbA. The ability of such chimeric (hybrid) designed 
enzymes to function as disulfide isomerases in Vivo, and their 
in vitro characterization, was demonstrated. The work 
described below shows that FkpA-DsbA chimeras, although 
lacking any DsbC sequences, result in VtPA yields compa 
rable to those provided by wild-type DsbC. In particular, 
FkpA-DsbA2, FkpA-DsbA3, and FkpA-DsbA4 supported 
the folding of vtPA with yields 80,55, and 67% of the yield of 
active protein obtained with wild-type DsbC (FIG. 2A). In 
addition, only background levels of active vtPA were detected 
in cells lacking DsbD, and expressing any of the FkpA-DsbA 
chimeras. Without being bound by any theory, this suggests 
that the activity of the chimera proteins depends on their 
recycling by DsbD and leads to the rearrangement of non 
native disulfide bonds. 
Definitions: 
As used herein, “dsbA' refers to a gene encoding the 
bacterial periplasmic protein known in the literature as DsbA. 
In one embodiment, the dsbA gene may comprise a sequence 
encoding the mature DsbA polypeptide of SEQID NO:3. A 
DsbA homolog may also be used in a chimeric protein of the 
present invention. Homologs of Such genes are known from 
numerous bacterial sources, both gram-positive and gram 
negative, including members of the Bacillaceae (e.g., Gen 
BankYP 08.1862), Enterobacteriaceae (e.g., Shevchiket al., 
1995), Pseudomonadaceae (e.g., Kloeket al., 2000: GenBank 
U84726), Anaplasmataceae (e.g., McBride et al., 2002), and 
others. In certain embodiments, chimeric proteins of the 
present invention may comprise a DsbA fragment comprising 
a C-terminal thioredoxin domain and/or thioredoxin activity. 
In various embodiments, a variant of a DsbA protein may be 
used with the present invention; for example, a chimeric 
protein of the present invention may comprise a DsbA deriva 
tive, wherein the DsbA derivative has thioredoxin activity and 
exhibits about 70, 75,81, 85,90,91, 92,93, 94, 95, 96, 97,98, 
99.99.5, or about 99.9 percent sequence identity with a wild 
type DsbA amino acid sequence. 
As used herein, “fkpA refers to a gene encoding an FK506 














known in the literature as FkpA (e.g., SEQID NO:1). A FkpA 
homolog or a FkpA homolog fragment may also be used in a 
chimeric protein of the present invention. Homologs of Such 
FKBP genes are known from numerous bacterial sources, 
including members of the Enterobacteriaceae (e.g., GenBank 
AAN44828. AAL22316) Pseudomonadaceae (e.g., Isaki et 
al., 1990) Corynebacteraceae (e.g., GenBank BX927 150), 
and others. As noted, these genes may be isolated from any 
bacterial source, for example the dsbA gene from E. coli as 
described in Collet and Bardwell (2002); or the fkpA gene 
described in Horne etal. (1995; GenBank accession L28082), 
or Arie et al. (2001), encoding a bacterial periplasmic protein. 
Variants of genes encoding functional DsbA or FkpA proteins 
are also contemplated. In certain embodiments, chimeric pro 
teins of the present invention may comprise a FkpA fragment, 
wherein the FkpA fragment comprises a Substrate binding 
region and allows for dimerization. In various embodiments, 
a variant of a FkpA protein may be used with the present 
invention; for example, a chimeric protein of the present 
invention may comprise a fragment of a FkpA derivative, 
wherein the fragment of a FkpA derivative has substrate bind 
ing activity, allows for dimerization, and displays about 70, 
75, 81, 85,90,91, 92,93, 94, 95, 96, 97,98, 99,99.1, 99.5, or 
about 99.9 percent sequence identity with a wild-type FkpA 
amino acid sequence. 
As used herein, “signal sequence' or 'signal polypeptide' 
refers to a peptide that can be used to secrete a heterologous 
polypeptide into the periplasm or medium of the cultured 
bacteria or to secrete proteins into the periplasm. A signal 
sequence is understood to direct post-translational transport 
of a protein. The signal sequence for a heterologous polypep 
tide may be homologous to the bacteria, or they may be 
heterologous, including signals native to the polypeptide 
being produced in the bacteria. Various signal peptides are 
known in the art, and these peptides are typically 3-60 amino 
acids long. 
An "over-expressed gene product is one that is expressed 
at levels greater than normal endogenous expression for that 
gene product. It can be accomplished, e.g., by introducing a 
recombinant construct that directs expression of a gene prod 
uct in a host cell, or by altering basal levels of expression of an 
endogenous gene product, e.g., by inducing its transcription. 
The promoters of this invention may be “inducible' pro 
moters, i.e., promoters which direct transcription at an 
increased or decreased rate upon binding of a transcription 
factor. Alternatively, the promoters may be “constitutive.” 
i.e., an unregulated promoter that allows for continual tran 
Scription of its associated gene. 
“Transcription factors' as used herein include any factors 
that can bind to a regulatory or control region of a promoter 
and thereby effect transcription. The synthesis or the pro 
moter binding ability of a transcription factor within the host 
cell can be controlled by exposing the host to an “inducer or 
removing an inducer from the host cell medium. Accordingly, 
to regulate expression of an inducible promoter, an inducer is 
added or removed from the growth medium of the host cell. 
Various inducible promoters are known in that art and may be 
used with the present invention; these inducible promoters 
include chemically-regulated promoters (e.g., alcohol-regu 
lated, tetracycline-regulated, steriod-regulated, metal-regu 
lated, and pathogenesis-regulated promoters) and physically 
regulated promoters (e.g., light-regulated promoters or 
temperature-regulated promoters, e.g., as described in U.S. 
Pat. No. 5,447,858). 
As used herein, the phrase “induce expression” means to 
increase the amount of transcription of a specific gene by 
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exposing a cell containing the gene to an effector or inducer, 
which results in increased transcription of the gene. 
An “inducer is a chemical or physical agent which, when 
given to a population of cells, will increase the amount of 
transcription from specific genes. These are usually small 
molecules whose effects are specific to particular operons or 
groups of genes, and can include Sugars, phosphate, alcohol, 
metal ions, hormones, heat, cold, and the like. For example, 
isopropylthio-f-galactoside (IPTG) and lactose are inducers 
of the tac promoter, and L-arabinose is a Suitable inducer of 
the arabinose promoter. The phogene promoter. Such as phoA 
and pho5, is inducible by low phosphate concentrations in the 
medium. 
As used herein, "polypeptide' or “polypeptide of interest' 
refers generally to peptides and proteins having more than 
about ten amino acids, e.g., from 1-1000, 1-500. 1-400, 
1-300, 1-200 amino acids or any number derivable therein. 
Preferably, the polypeptides are “exogenous” meaning that 
they are "heterologous', i.e., foreign to the host cell being 
utilized, such as a human protein produced by a CHO cell, or 
a yeast polypeptide produced by a mammalian cell, or a 
human polypeptide produced from a human cell line that is 
not the native source of the polypeptide. 
Heterologous Polypeptides 
Polypeptides of the present invention (e.g., a FkpA-Dsb 
polypeptide) may be used to allow for proper folding and 
disulfide bond formation of a heterologously expressed mam 
malian protein. It is anticipated that a practitioner may use the 
present invention with virtually any protein containing, e.g., 
two or more non-native disulfide bonds. Examples of mam 
malian polypeptides that may be expressed heterologously in 
a bacterial cell with a polypeptide of the present invention to 
generate a disulfide bond in the mammalian polypeptide 
include molecules Such as, e.g., renin, a growth hormone 
(e.g., human growth hormone, bovine growth hormone, etc.), 
growth hormone releasing factor, growth factors, a hormone 
(e.g., parathyroid hormone, thyroid stimulating hormone), 
lipoproteins, al-antitrypsin, insulin or an insulin chain (e.g., 
insulin A-chain, insulin B-chain), proinsulin, thrombopoietin, 
follicle stimulating hormone, calcitonin, luteinizing hor 
mone, glucagon, a clotting factor (e.g., factor VIIIC, factor 
IX, tissue factor, von Willebrands factor), anti-clotting factors 
Such as Protein C, an atrial naturietic factor, lung Surfactants, 
a plasminogen activator Such as human tRA or urokinase, 
mammalian trypsin inhibitor, brain-derived neurotrophic 
growth factor (BDNF), a kallikrein, CTNF, gp120, anti-HER 
2, DNases, IGF-I, IGF-II, brain IGF-I, human chorionic 
gonadotropin, mammalian pancreatic trypsin inhibitors, an 
antibody fragment, protease inhibitors, therapeutic enzymes, 
lymphokines, cytokines, immunotoxins, bombesin, throm 
bin, tumor necrosis factor -C. and -3, enkephalinase, a serum 
albumin (e.g., human serum albumin, bovine serum albumin, 
etc.), a mullerian-inhibiting Substance, relaxin A-chain, 
relaxin B-chain, prorelaxin, mouse gonadotropin-associated 
peptide, a microbial protein (e.g., B-lactamase), inhibin, 
activin, vascular endothelial growth factor (VEGF), a recep 
tor for a hormone or growth factors, integrin, protein A or D, 
a rheumatoid factor, a neurotrophic factors such as neurotro 
phin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve 
growth factor such as NGF-B, a cardiotrophin (cardiac hyper 
trophy factor) such as cardiotrophin-1 (CT-1), platelet-de 
rived growth factor (PDGF), a fibroblast growth factor such as 
-C. FGF and -3 FGF, epidermal growth factor (EGF), a trans 
forming growth factor (TGF). TGF-C., a TGF-B (e.g., TGF 
|B1, TGF-B2, TGF-B3, TGF-B4, or TGF-B5), insulin-like 
growth factor-I and -II (IGF-I and IGF-II), des(1-3)-IGF-I 














CD protein (e.g., CD-3, CD-4, CD-8, CD-19), erythropoietin, 
osteoinductive factors, immunotoxins, bone morphogenetic 
proteins (BMPs), interferons such as interferon-C, -?3, and -y, 
colony stimulating factors (CSFs) (e.g., M-CSF, GM-CSF, 
G-CSF), interleukins (Ils) such as IL-1 to IL-10, anti-HER-2 
antibody, Superoxide dismutase, T-cell receptors, Surface 
membrane proteins, decay accelerating factor, viral antigens 
Such as a portion of the AIDS envelope, transport proteins, 
homing receptors, addressins, regulatory proteins, antibod 
ies, antigens such as gp120(IIIb), and derivatives or active 
fragments of any of the peptides listed herein. 
The polypeptides may be native or mutated polypeptides, 
and preferred sources for Such mammalian polypeptides 
include human, bovine, equine, porcine, lupine, and rodent 
Sources. In certain embodiments, human proteins are used. 
In one embodiment, in addition to native tRA, the inventors 
contemplate the production of tRA variants and derivatives 
using the disclosed methods and compositions. Examples of 
tPA variants contemplated to be useful in the practice of the 
present invention include: 
(1) tea variants which have an extra glycosylation site at 
amino acid positions 103-105, the native glycosylation site 
removed at position 117, and at least one amino acid Substi 
tuted in the 296-299 amino acid region of native human teA. 
A specific molecule within this group is T103N, N117O. 
KHRR (92.96-299)AAAA tPA (TNK tA), where the amino 
acids replaced are indicated to the left and the amino acids 
substituted for them to the right of the amino acid position(s) 
shown. These molecules, which have an extended half-life 
and improved fibrin specificity as compared to wild-type 
human tRA, and show Substantial resistance to the fast acting 
plasminogen activator inhibitor (PAI-1), are specifically dis 
closed, for example, in Intl. Pat. Appl. Publ. No. WO/93/ 
24635. 
(2) N-terminally truncated tRA variants, and specifically 
the plasminogen activator K2P (BM 06.002) described, for 
example, in Eur. Pat. Appl. No. EP 0382174. These variants 
contain the kringle 2 (K2) and protease (P) domains of human 
tPA, and due to its expression in E. coli is present in an 
unglycosylated form. K2P has been described to have a 
reduced clearance and a longer plasma half-life. Other tRA 
variants which may be used with the present invention include 
those described in Eur. Pat. Appl. No. EP 196920; Eur. Pat. 
Appl. No. EP207589; Aust. Pat. Appl. No. AU 61804/86: Eur. 
Pat. Appl. No. EP 231624; Eur. Pat. Appl. No. EP 289508: 
Eur. Pat. Appl. No. EP 234051; Eur. Pat. Appl. No. EP 
263172: Eur. Pat. Appl. No. EP24208; Eur. Pat. Appl. No. EP 
292009; Eur. Pat. Appl. No. EP297066: Eur. Pat. Appl. No. 
EP302456: Eur. Pat. Appl. No. EP379890; Jolyet al., (1997). 
(3) Vampire bat tRAS (BatPAs), as disclosed, e.g., in Eur. 
Pat. Appl. No. EP 3521.19; and 
(4) A tA variant having cysteine at position 84 of native 
tPA replaced by serine (C84S tRA), described, e.g., in Suzuki 
et al. (1993). 
DNA Expression 
The expression “control sequences’ refers to DNA 
sequences necessary for the expression of an operably linked 
coding sequence in a particular host organism. The control 
sequences that are suitable for bacteria include the alkaline 
phosphatase promoter, optionally an operator sequence, and a 
ribosome-binding site. 
A nucleic acid is “operably” or “operatively' linked when 
it is placed into a functional relationship with another nucleic 
acid sequence. For example, DNA for a presequence or secre 
tory leader is operably/operatively linked to DNA for a 
polypeptide if it is expressed as a preprotein that participates 
in the secretion of the polypeptide; a promoter or enhancer is 
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operably/operatively linked to a coding sequence if it affects 
the transcription of the sequence; or a ribosome binding site is 
operably linked to a coding sequence if it is positioned so as 
to facilitate translation. Linking can be accomplished by liga 
tion at convenient restriction sites. If such sites do not exist, 
synthetic oligonucleotide adaptors or linkers may be used in 
accordance with conventional practice. 
Cell Lines 
As used herein, the expressions “cell”, “cell line', and “cell 
culture' are used interchangeably and all Such designations 
include progeny. Thus, the words “transformants' and “trans 
formed cells' include the primary subject cell and cultures 
derived there from without regard for the number of transfers. 
It is also understood that all progeny may not be precisely 
identical in DNA content, due to deliberate or inadvertent 
mutations. Mutant progeny that have the same function or 
biological activity as screened for in the originally trans 
formed cell are included. Where distinct designations are 
intended, it will be clear from the context. 
DsbC and DsbG 
DsbC is a soluble periplasmic oxidoreductase which is 
thought to act in parallel with DsbA (Missiakas et al., 1994: 
Bardwell et al., 1993; Bardwell, 1994). Unlike DsbA which 
exhibits low disulfide isomerase activity in vitro, DsbC has 
been shown to be an efficient catalyst of disulfide bond 
isomerization (Zapun et al., 1995). 
DsbG is a soluble periplasmic oxidoreductase which has 
properties similar to DsbC. Unlike DsbA which exhibits low 
disulfide isomerase activity in vitro, DsbG is an efficient 
catalyst of disulfide bond isomerization (U.S. Pat. No. 6,083, 
715). 
Methods of Nucleic Acid Delivery and DNA Transforma 
tion 
In certain embodiments, the present invention provides 
recombinant host cells transformed with polynucleotides 
which encode novel hybrid disulfide bond isomerases and 
particular disulfide bond-containing polypeptides of interest, 
as well as transgenic cells derived from those transformed or 
transfected cells. In particular embodiments, a recombinant 
host cell of the present invention is transformed with a poly 
nucleotide comprising a sequence encoding a hybrid FkpA 
DsbA polypeptide and a polynucleotide comprising a 
sequence encoding a heterologous polypeptide that contains 
disulfide bonds, for instance tissue plasminogen activator 
(tPA) or a variant of tRA. Means of transforming cells with 
exogenous polynucleotides such as DNA molecules are well 
known in the art and include techniques such as calcium 
phosphate- or DEAE-dextran-mediated transfection, proto 
plast fusion, electroporation, liposome mediated transfection, 
direct microinjection and adenovirus infection (Sambrook et 
al., 1989). 
For example, electroporation can be used to transform cells 
Such as bacterial cells. The application of brief, high-voltage 
electric pulses to a cell culture can lead to the formation of 
nanometer-sized pores in the cell membrane. DNA is taken 
directly into the cytoplasm either through these pores or as a 
consequence of the redistribution of membrane components 
that accompanies closure of the pores. Electroporation can be 
extremely efficient and can be used both for transient expres 
sion of cloned genes and for establishment of cell lines that 
carry integrated copies of a gene of interest. Electroporation, 
in contrast to calcium chloride-mediated transformation, fre 
quently gives rise to high numbers of target cells being trans 
formed with the foreign DNA. 
Liposome and Nanocapsule Transformation 
Liposome transfection involves encapsulation of DNA and 














with the cell membrane. The mechanism of how DNA is 
delivered into the cell is unclear but transfection efficiencies 
can be as high as 90%. 
In certain embodiments, the inventors contemplate the use 
of liposomes and/or nanocapsules for the introduction of 
particular peptides or nucleic acid segments into host cells. 
Such formulations may be preferred for the introduction of 
nucleic acids, peptides, and/or antibodies derived therefrom. 
The formation and use of liposomes is generally known to 
those of skill in the art (see, e.g., Couvreur et al., 1977 and 
Gabizon and Papahadjopoulos, 1988). 
Recombinant Expression of Heterologous Proteins in Bac 
teria 
The present inventors contemplate expression of polypep 
tides in conjunction with a disulfide bond isomerase of the 
present invention. A technique often employed by those 
skilled in the art of protein production is to obtain a so-called 
“recombinant version of the protein, to express it in a recom 
binant cell and to obtain the protein from such cells. These 
techniques are based upon the “cloning of a DNA molecule 
encoding the protein from a DNA library, i.e., on obtaining a 
specific DNA molecule distinct from other portions of DNA. 
This can be achieved by, for example, cloning a cDNA mol 
ecule, or cloning a genomic-like DNA molecule. Techniques 
Such as these would also, of course, be appropriate for the 
production of a disulfide bond-containing polypeptide in 
accordance with the present invention. 
The first step in Such cloning procedures is the screening of 
an appropriate DNA library, such as a rat, human, bovine, or 
other mammalian-derived library. The screening procedure 
may be an expression screening protocol employing antibod 
ies directed against the protein, or activity assays. Alterna 
tively, screening may be based on the hybridization of oligo 
nucleotide probes, designed from a consideration of portions 
of the amino acid sequence of the protein, or from the DNA 
sequences of genes encoding related proteins. The operation 
of such screening protocols are well known to those of skill in 
the art and are described in detail in the scientific literature, 
for example, in Sambrook et al. (1989). Moreover, as the 
present invention encompasses the cloning of genomic seg 
ments as well as cDNA molecules, it is contemplated that 
other Suitable methods known to those in the art, such as, e.g., 
those described by Spoerel et al. (1987), may also be used in 
connection with cloning a disulfide bond-containing 
polypeptide, or alternatively to express a hybrid polypeptide, 
Such as a hybrid FkpA-DsbA polypeptide (e.g., that displays 
disulfide bond isomerase, and/or chaperone activity in vivo or 
in vitro and directs the folding and isomerization of disulfide 
bonds contained within a disulfide bond-containing polypep 
tides of interest). 
After identifying appropriate DNA molecules, they may be 
inserted into any one of the many vectors currently known in 
the art and transferred to a host cell where it will direct the 
expression and production of the so-called recombinant Ver 
sion of the protein. This is also, of course, routinely practiced 
in the art and described in various publications, such as, e.g., 
Sambrook et al. (1989). Such DNA segments may be con 
tained on a single plasmid vector, or alternatively, the 
isomerase/chaperone may be encoded by a nucleic acid 
sequence on one vector and the disulfide bond-containing 
polypeptide of interest may be present on a second plasmid 
vector which is compatible for co-residence in a single host 
cell with the first plasmid vector comprising the isomerase? 
chaperone sequence. The selection of plasmid vectors is well 
known to those of skill in the art, and Such a selection may be 
based on the incompatibility grouping of Such vectors (IncP. 
IncCR, etc.). Virtually any such plasmid vectors may be used in 
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the practice of the invention. In one embodiment, preferred 
replicons include p ACYC184 and pTI 103. 
It will be understood that recombinant disulfide bond-con 
taining polypeptides may differ from naturally-produced 
polypeptides in certain ways. In particular, the degree of 
post-translational modifications. Such as, for example, glyco 
sylation and phosphorylation may be different between the 
recombinant and natural forms. 
Recombinant clones expressing nucleic acid segments 
which encode eukaryotic disulfide-bond containing polypep 
tides may be used to prepare purified recombinant polypep 
tides, purified polypeptide-derived antigens as well as mutant 
or variant recombinant protein species in significant quanti 
ties. In particular, the invention provides for the production of 
recombinant polypeptides in Substantial quantities from bac 
terial host cells. 
Additionally, by application of techniques such as DNA 
mutagenesis, the present invention allows the ready prepara 
tion of so-called “second generation' molecules having 
modified or simplified protein structures. Second generation 
proteins will typically share one or more properties in com 
mon with the full-length polypeptides, such as a particular 
antigenic/immunogenic epitopic core sequences, or particu 
lar catalytic sites, active sites, or ligand binding domains, etc. 
Epitopic sequences can be provided on relatively short mol 
ecules prepared from knowledge of the peptide or encoding 
DNA sequence information. Such variant molecules may not 
only be derived from selected immunogenic/antigenic 
regions of the proteinstructure, but may additionally, or alter 
natively, include one or more functionally equivalent amino 
acids selected on the basis of similarities or even differences 
with respect to the natural sequence. This is particularly desir 
able in the preparation of recombinant polypeptides having 
enhanced or Superior stability, activity, binding, or affinity for 
substrates and the like. 
The general process of recombinant expression of proteins 
in bacterial hosts, and particularly Gram-negative hosts, is 
well-known to those of skill in the art. It is generally benefi 
cial for the methods described herein that the DNA sequence 
encoding the particular eukaryotic protein of interest to be 
secreted be operatively linked to a DNA sequence which 
encodes a signal peptide Sufficient for the translocation of the 
recombinant polypeptide to the periplasmic space of the bac 
terial host cell. As is well-known, operative links between 
Such DNA sequences mean that a translational fusion exists 
between the heterologous protein and the signal peptide. As a 
rule, such signal peptides form the N-terminal portion of the 
secreted heterologous protein. Signal sequences which pro 
mote protein translocation to the periplasmic space of Gram 
negative bacterial are well-known, as exemplified by those 
described herein. The E. coli Omp.A, Lipp, LamB, MalE, 
PelB, and StII leader peptide sequences have been success 
fully used in many applications as signal sequences to pro 
mote protein secretion in bacterial cells Such as those used 
herein, and are all contemplated to be useful in the practice of 
the invention. 
Promoters, Enhancers, and Signal Sequence Elements 
Promoter elements regulate the frequency of transcrip 
tional initiation. Typically, these are located in the region 
30-110 bp upstream of the start site, although a number of 
promoters have recently been shown to contain functional 
elements downstream of the start site as well. The spacing 
between elements is flexible, so that promoter function is 
preserved when elements are inverted or moved relative to 
one another. In the tk promoter, the spacing between elements 












decline. Depending on the promoter, it appears that individual 
elements can function either cooperatively or independently 
to activate transcription. 
Enhancers were originally detected as genetic elements 
that increased transcription from a promoter located at a 
distant position on the same molecule of DNA. This ability to 
act over a large distance had little precedent in classic studies 
of prokaryotic transcriptional regulation. Subsequent work 
showed that regions of DNA with enhancer activity are orga 
nized much like promoters. That is, they are composed of 
many individual elements, each of which binds to one or more 
transcriptional proteins. 
Examples of useful promoters include the lac-lpp promoter 
which is well-known in the art. Other non-limiting examples 
of promoters contemplated to be useful in the practice of the 
invention include the ara, tet, tac, trc, trp, phoA, P. W. 
1pp. and T7 promoters. 
Site-Specific Mutagenesis 
Site-specific mutagenesis is a technique useful in the 
preparation of individual peptides, or biologically functional 
equivalent proteins or peptides, through specific mutagenesis 
of the underlying DNA. The technique, well-known to those 
of skill in the art, further provides the ability to prepare and 
test sequence variants, for example, incorporating one or 
more of the foregoing considerations, by introducing one or 
more nucleotide sequence changes into the DNA. Site-spe 
cific mutagenesis allows the production of mutants through 
the use of specific oligonucleotide sequences which encode 
the DNA sequence of the desired mutation, as well as a 
Sufficient number of adjacent nucleotides, to provide a primer 
sequence of Sufficient size and sequence complexity to form 
a stable duplex on both sides of the deletion junction being 
traversed. Typically, a primer of about 14 to about 25 nucle 
otides in length is preferred, with about 1 to about 10 residues 
on both sides of the junction of the sequence being altered. 
In general, the technique of site-specific mutagenesis is 
well known in the art, as exemplified by various publications. 
As will be appreciated, the technique typically employs a 
phage vector which exists in both a single-stranded and 
double-stranded form. Typical vectors useful in site-directed 
mutagenesis include vectors such as the M13 phage. These 
phage are readily commercially-available and their use is 
generally well-known to those skilled in the art. Double 
Stranded plasmids are also routinely employed. 
PCR-based strand overlap extension (SOE) for cloning and 
site-directed mutagenesis was utilized for preparing the 
nucleic acid compositions of the present invention. The tech 
niques of PCR are well-known to those of skill in the art (e.g., 
U.S. Pat. Nos. 4,683, 195; 5,023,171). The SOE procedure 
involves a two-step PCR protocol, in which a complementary 
pair of internal primers (B and C) are used to introduce the 
appropriate nucleotide changes into the wild-type sequence. 
In two separate reactions, flanking PCR primer A (restriction 
site incorporated into the oligo) and primer D (restriction site 
incorporated into the oligo) are used in conjunction with 
primers B and C, respectively to generate PCR products AB 
and CD. The PCR products are purified by agarose gel elec 
trophoresis and the two overlapping PCR fragments AB and 
CD are combined with flanking primers A and D and used in 
a second PCR reaction. The amplified PCR product is agarose 
gel purified, digested with the appropriate enzymes, ligated 
into an expression vector, and may be transformed into E. coli 
JM101, XL1-BlueTM (Stratagene, La Jolla, Calif.), JM105, 
TG1 (Carter et al., 1985), or other such suitable cells as 
deemed appropriate depending upon the particular applica 
tion of the invention. Clones are isolated and the mutations 
can be confirmed by sequencing of the isolated plasmids. 
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Beginning with the native gene sequences (for example, the 
nucleic acid sequences encoding a eukaryotic disulfide-bond 
containing polypeptide Such as tA or the like), Suitable 
clones and Subclones may be made in the appropriate vectors 
from which site-specific mutagenesis may be performed. 
Biological Functional Equivalents 
Modification and changes may be made in the structure of 
a peptide of the present invention, and/or the DNA segment 
which encodes it, and result in a functional molecule that 
encodes a protein or peptide with desirable characteristics. 
For example, FkpA and DsbA could be altered in accordance 
with the invention (e.g., via a substitution or deletion muta 
tion, etc.). The following is a discussion based upon changing 
the amino acids of a protein to create an equivalent, or even an 
improved, second-generation molecule. 
For example, certain amino acids may be substituted for 
other amino acids in a protein structure without appreciable 
loss of interactive binding capacity with structures such as, 
for example, antigen-binding regions of antibodies orbinding 
sites on Substrate molecules. Since it is the interactive capac 
ity and nature of a protein that defines that protein's biological 
functional activity, certain amino acid sequence Substitutions 
can be made in a protein sequence, and, of course, its under 
lying DNA coding sequence, and nevertheless obtain a pro 
tein with like properties. It is thus contemplated by the inven 
tors that various changes may be made in the peptide 
sequences of the disclosed compositions, or corresponding 
DNA sequences which encode said peptides without appre 
ciable loss of their biological utility or activity. 
In making Such changes, the hydropathic index of amino 
acids may be considered. The importance of the hydropathic 
amino acid index in conferring interactive biologic function 
on a protein is generally understood in the art (Kyte and 
Doolittle, 1982). It is accepted that the relative hydropathic 
character of the amino acid contributes to the secondary struc 
ture of the resultant protein, which in turn defines the inter 
action of the protein with other molecules, for example, 
enzymes, Substrates, receptors, DNA, antibodies, antigens, 
and the like. Each amino acid has been assigned a hydropathic 
index on the basis of their hydrophobicity and charge char 
acteristics (Kyte and Doolittle, 1982), these are: isoleucine 
(+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); 
cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); 
glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan 
(-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2): 
glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); aspar 
agine (-3.5); lysine (-3.9); and arginine (-4.5). 
It is known in the art that certain amino acids may be 
Substituted by otheramino acids having a similar hydropathic 
index or score and still result in a protein with similar bio 
logical activity, ie. Still obtain a biological functionally 
equivalent protein. In making Such changes, the Substitution 
of amino acids whose hydropathic indices are within t2 is 
preferred, those which are within +1 are particularly pre 
ferred, and those within +0.5 are even more particularly pre 
ferred. It is also understood in the art that the substitution of 
like amino acids can be made effectively on the basis of 
hydrophilicity. U.S. Pat. No. 4,554,101, states that the great 
est local average hydrophilicity of a protein, as governed by 
the hydrophilicity of its adjacentamino acids, correlates with 
a biological property of the protein. 
As detailed in U.S. Pat. No. 4,554,101, the following 
hydrophilicity values have been assigned to amino acid resi 
dues: arginine (+3.0); lysine (+3.0); aspartate (+3.0+1): 
glutamate (+3.0t1); serine (+0.3); asparagine (+0.2): 
glutamine (+0.2); glycine (O); threonine (-0.4); proline 














methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine 
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
(-3.4). It is understood that an amino acid can be substituted 
for another having a similar hydrophilicity value and still 
obtain a biologically equivalent, and in particular, an immu 
nologically equivalent protein. In Such changes, the Substitu 
tion of amino acids whose hydrophilicity values are within +2 
is preferred, those which are within +-0.1 are particularly 
preferred, and those within +0.5 are even more particularly 
preferred. 
As outlined above, amino acid substitutions are generally 
therefore based on the relative similarity of the amino acid 
side-chain Substituents, for example, their hydrophobicity, 
hydrophilicity, charge, size, and the like. Exemplary Substi 
tutions which take various of the foregoing characteristics 
into consideration are well known to those of skill in the art 
and include: arginine and lysine; glutamate and aspartate; 
serine and threonine; glutamine and asparagine; and valine, 
leucine and isoleucine. 
MODES FOR CARRYING OUT THE INVENTION 
In one embodiment of the invention, expression of a hybrid 
disulfide bond isomerase gene may be induced prior to het 
erologous gene expression. The heterologous polypeptide 
and the FkpA-DsbA hybrid (chimera) polypeptide may be 
secreted into the periplasm, or the heterologous polypeptide 
may be secreted into the culture medium of the bacteria which 
may also contain a nucleic acid encoding the polypeptide. In 
certain embodiments, the polypeptide is recovered from the 
periplasm of the bacteria. 
The flkp.A and dsbA genes used to create the FkpA-DsbA 
chimera may be derived from any bacterial Source, e.g., from 
E. coli. A gene encoding the chimera polypeptide may be 
separately placed from a gene encoding a heterologous 
polypeptide if the nucleic acids are on the same vector. In 
addition, the nucleic acid encoding the FkpA-DsbA hybrid 
and the nucleic acid encoding the heterologous polypeptide 
will often be under separate, different inducible promoters so 
that induction of expression can occur in the required sequen 
tial order. The nucleic acid encoding the FkpA-DsbA chimera 
and the nucleic acid encoding the heterologous polypeptide 
may be integrated into the host cell genome or contained on 
autonomously replicating plasmids. 
In one embodiment, the bacteria comprises two separate 
vectors respectively containing the nucleic acid encoding the 
engineered FkpA-DsbA chimera polypeptide and the nucleic 
acid encoding the heterologous polypeptide. 
In another embodiment, the nucleic acid encoding the 
FkpA-DsbA chimera polypeptide and the nucleic acid encod 
ing the heterologous polypeptide are contained on the same 
vector but are under the control of separate inducible promot 
ers and separate signal sequences. 
In a third embodiment, the nucleic acid encoding the 
FkpA-DsbA chimera polypeptide and the nucleic acid encod 
ing the heterologous polypeptide are contained on the same 
vector and are under the control of a single promoter. 
In a fourth embodiment the FkpA and DsbA domains of the 
disulfide isomerase are encoded by different vectors. Each of 
the FkpA and DsbA proteins are expressed as fusions to 
dimerizing domains such as those derived from well known 
heterodimeric leucine Zipper (e.g., from the transcriptiona 
activator SCN4). The FkpA and DsbA fusions to the respec 
tive halves of the leucine zipper associate in the bacterial 
periplasm to form a protein, comprising of four polypeptides: 
two FkpA chains that associate with two DsbA chains via 
leucine Zipper interactions. 
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The heterologous nucleic acid (e.g., cDNA or genomic 
DNA) can be suitably inserted into a replicable vector for 
expression in the bacterium under the control of a suitable 
promoter for bacteria. Many vectors are available for this 
purpose, and selection of the appropriate vector will depend 
mainly on the size of the nucleic acid to be inserted into the 
vector and the particular host cell to be transformed with the 
vector. Each vector contains various components depending 
on its function (amplification of DNA or expression of DNA) 
and the particular host cell with which it is compatible. The 
vector components for bacterial transformation generally 
include, but are not limited to, one or more of the following: 
a signal sequence, an origin of replication, one or more 
marker genes, and an inducible promoter. 
In general, plasmid vectors containing replicon and control 
sequences that are derived from species compatible with the 
host cell are used in connection with bacterial hosts. The 
vector ordinarily carries a replication site, as well as marking 
sequences that are capable of providing phenotypic selection 
in transformed cells. For example, E. coli may be transformed 
using pBR322, a plasmid derived from an E. coli species (see, 
e.g., Bolivar et al., 1977). pBR322 contains genes for ampi 
cillin and tetracycline resistance and thus provides easy 
means for identifying transformed cells. The pBR322 plas 
mid, or other microbial plasmid or phage, also generally 
contains, or is modified to contain, promoters that can be used 
by the microbial organism for expression of the selectable 
marker genes. 
The DNA encoding the polypeptide of interest herein may 
be expressed not only directly, but also as a fusion with 
another polypeptide, preferably a signal sequence or other 
polypeptide having a specific cleavage site at the N-terminus 
of the mature polypeptide. In general, the signal sequence 
may be a component of the vector, or it may be a part of the 
polypeptide DNA that is inserted into the vector. The heter 
ologous signal sequence selected should be one that is recog 
nized and processed (i.e., cleaved by a signal peptidase) by 
the host cell. For bacterial host cells that do not recognize and 
process the native polypeptide signal sequence, the signal 
sequence is Substituted by a bacterial signal sequence 
selected, for example, from the group consisting of the alka 
line phosphatase, penicillinase, 1 pp, or heat-stable entero 
toxin II leaders. 
Both expression and cloning vectors contain a nucleic acid 
sequence that enables the vector to replicate in one or more 
selected host cells. Generally, in cloning vectors this 
sequence is one that enables the vector to replicate indepen 
dently of the host chromosomal DNA, and includes origins of 
replication or autonomously replicating sequences. Such 
sequences are well known for a variety of bacteria. The origin 
of replication from the plasmid pPR322 is suitable for most 
Gram-negative bacteria. 
Expression and cloning vectors also generally contain a 
selection gene, also termed a selectable marker. This gene 
encodes a protein necessary for the Survival or growth of 
transformed host cells grown in a selective culture medium. 
Host cells not transformed with the vector containing the 
selection gene will not Survive in the culture medium. Typical 
selection genes encode proteins that (a) confer resistance to 
antibiotics or other toxins, e.g., amplicillin, neomycin, meth 
otrexate, or tetracycline, (b) complement auxotrophic defi 
ciencies, or (c) Supply critical nutrients not available from 
complex media, e.g., the gene encoding D-alanine racemase 
for Bacilli. One example of a selection scheme utilizes a drug 
to arrest growth of a host cell. Those cells that are successfully 
transformed with a heterologous gene produce a protein con 













The expression vector for producing a heterologous 
polypeptide may also contain an inducible promoter that is 
recognized by the host bacterial organism and is operably 
linked to the nucleic acid encoding the polypeptide of inter 
est. It may also contain a separate inducible promoter oper 
ably linked to the nucleic acid encoding the FkpA-DsbA 
chimera. Inducible promoters suitable for use with bacterial 
hosts include the B-lactamase and lactose (lac) promoter sys 
tems (Chang et al., 1978; Goeddelet al., 1979), the arabinose 
(ara) promoter system (Guzman et al., 1995), alkaline phos 
phatase (phoA), a tryptophan (trp) promoter system (Goed 
del, 1980: Eur. Pat. Appl. Publ. No. EP36,776), promoter, 
and hybrid promoters such as the tac promoter. However, 
other known bacterial inducible promoters are suitable. Their 
nucleotide sequences have been published, thereby enabling 
a skilled worker to operably ligate them to DNA encoding the 
polypeptide of interest or to thefkpA-dsbA hybrid gene (Sie 
benlist et al., 1980) using linkers or adaptors or other methods 
to supply any required restriction sites. 
Promoters for use in bacterial systems also generally con 
tain a Shine-Dalgamo (S.D.) sequence operably linked to the 
DNA encoding the polypeptide of interest. The promoter can 
be removed from the bacterial source DNA by restriction 
enzyme digestion and inserted into the vector containing the 
desired DNA. Construction of suitable vectors containing one 
or more of the above-listed components employs standard 
ligation techniques. Isolated plasmids or DNA fragments are 
cleaved, tailored, and re-ligated in the form desired to gener 
ate the plasmids required. 
Suitable bacteria for this purpose include Archaebacteria 
and Eubacteria, especially Eubacteria, and most preferably 
Enterobacteriaceae. Examples of useful bacteria include 
Escherichia, Enterobacter, Azotobacter, Erwinia, Bacillus, 
Pseudomonas, Klebsiella, Proteus, Salmonella, Serratia, 
Shigella, Rhizobia, and Paracoccus. Suitable E. coli hosts 
include E. coli SF1 10, E. coli 294 (ATCC 31446), E. coli B, 
and E. coli 1776 (ATCC 31537). These examples are illus 
trative rather than limiting. Mutant cells of any of the above 
mentioned bacteria may also be employed, including ones 
that display an altered redox potential in their periplasm and/ 
or cytoplasm. It is, of course, necessary to select the appro 
priate bacteria taking into consideration replicability of the 
replicon in the cells of a bacterium. For example, E. coli, 
Serratia, or Salmonella species can be suitably used as the 
host when well known plasmids such as pBR322, pBR325, 
pACYC177, or pKN410 are used to supply the replicon. 
Host cells can be transfected and preferably transformed 
with the above-described expression vectors and cultured in 
conventional nutrient media modified as appropriate for 
inducing promoters, selecting transformants, or amplifying 
the genes encoding the desired sequences. 
Transfection refers to the taking up of an expression vector 
by a host cell whether or not any coding sequences are in fact 
expressed. Numerous methods of transfection are known to 
the ordinarily skilled artisan, for example, CaPO and elec 
troporation. Successful transfection is generally recognized 
when any indication of the operation of this vector occurs 
within the host cell. 
Transformation means introducing DNA into an organism 
so that the DNA is replicable, either as an extrachromosomal 
element or by chromosomal integrant. Depending on the host 
cell used, transformation can be done using standard tech 
niques appropriate to Such cells. The calcium treatment 
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employing calcium chloride, as described in section 1.82 of 
Sambrook et al., (1989), is generally used for bacterial cells 
that contain substantial cell-wall barriers. Another method for 
transformation employs polyethylene glycol/DMSO. Yet 
another method is the use of the technique termed electropo 
ration. 
Bacterial cells used to produce the polypeptide of interest 
for purposes of this invention can be cultured in suitable 
media in which the promoters for the nucleic acid encoding 
the heterologous polypeptide and for the nucleic acid encod 
ing DsbC can be artificially induced as described generally, 
e.g., in Sambrook et al. (1989). Examples of suitable media 
are given in U.S. Pat. Nos. 5,304,472 and 5,342,763. 
Any necessary Supplements besides carbon, nitrogen, and 
inorganic phosphate sources may also be included at appro 
priate concentrations introduced alone or as a mixture with 
another Supplement or medium Such as a complex nitrogen 
source. The pH of the medium may be any pH from about 5-9. 
depending mainly on the host organism. Preferably, the 
medium contains no reduced glutathione, and the bacteria are 
not cultured so as to over-express nucleic acid encoding the 
heat-shock transcription factor, RpoBI. 
Gene expression may be measured in a sample directly, for 
example, by conventional northern blotting to quantitate the 
transcription of mRNA (Thomas, 1980). Various labels may 
be employed, most commonly radioisotopes, particularly 'P. 
However, other techniques may also be employed. Such as 
using biotin-modified nucleotides for introduction into a 
polynucleotide. The biotin then serves as the site for binding 
to avidin or antibodies, which may be labeled with a wide 
variety of labels, such as radionuclides, fluorescers, enzymes, 
or the like. Alternatively gene expression may be measured 
based on the activity of the protein that is being produced. 
Procedures for observing whether an expressed or over 
expressed gene product is secreted are readily available to the 
skilled practitioner. Once the culture medium is separated 
from the host cells, for example, by centrifugation or filtra 
tion, the gene product can then be detected in the cell-free 
culture medium by taking advantage of known properties 
characteristic of the gene product. Such properties can 
include the distinct immunological, enzymatic, or physical 
properties of the gene product. 
For example, if an over-expressed gene product has a 
unique enzyme activity, an assay for that activity can be 
performed on the culture medium used by the host cells. 
Moreover, when antibodies reactive against a given gene 
product are available, such antibodies can be used to detect 
the gene product in any known immunological assay (e.g., as 
in Harlow and Lane, 1988). 
The secreted gene product can also be detected using tests 
that distinguish polypeptides on the basis of characteristic 
physical properties such as molecular weight. To detect the 
physical properties of the gene product, all polypeptides 
newly synthesized by the host cell can be labeled, e.g., with a 
radioisotope. Common radioisotopes that can be used to label 
polypeptides synthesized within a host cell include tritium 
(H), carbon-14 (''C), sulfur-35 (S), and the like. For 
example, the host cell can be grown in S-methionine or 
S-cysteine medium, and a significant amount of the S 
label will be preferentially incorporated into any newly syn 
thesized polypeptide, including the over-expressed heterolo 
gous polypeptide. The S-containing culture medium is then 
removed and the cells are washed and placed in fresh non 
radioactive culture medium. After the cells are maintained in 
the fresh medium for a time and under conditions sufficient to 
allow secretion of the S-radiolabeled expressed heterolo 













rated from the host cells. The molecular weight of the 
secreted, labeled polypeptide in the culture medium can then 
be determined by known procedures, e.g., polyacrylamide gel 
electrophoresis. Such procedures, and/or other procedures for 
detecting secreted gene products, are provided in Goeddel 
(1990), and Sambrook et al. (1989). 
For secretion of an expressed or over-expressed gene prod 
uct, the host cell is cultured under conditions sufficient for 
secretion of the gene product. Such conditions include, e.g., 
temperature, nutrient, and cell density conditions that permit 
secretion by the cell. Moreover, such conditions are those 
under which the cell can perform basic cellular functions of 
transcription, translation, and passage of proteins from one 
cellular compartment to another, as are knownto those skilled 
in the art. 
In practicing the process of this invention, the yield of 
biologically active polypeptide is generally increased, while 
yield of insoluble polypeptide is not changed or is decreased, 
i.e., yield of soluble and biologically active polypeptide is 
increased. 
The polypeptide of interest may be recovered from the 
periplasm or culture medium as a secreted Soluble polypep 
tide. It may be useful to purify the polypeptide of interest from 
recombinant cell proteins or polypeptides and from the 
FkpA-DsbA hybrid protein to obtain preparations that are 
Substantially homogeneous as to the polypeptide of interest. 
As a first step, the culture medium or lysate may be centri 
fuged to remove particulate cell debris. The membrane and 
soluble protein fractions may then be separated if necessary. 
The polypeptide may then be purified from the soluble pro 
tein fraction and from the membrane fraction of the culture 
lysate, depending on whether the polypeptide is membrane 
associated or, more preferably, completely soluble in the peri 
plasm or culture Supernatant. The polypeptide thereafter may 
be further solubilized and/or refolded, if necessary, and puri 
fied from contaminant soluble proteins and polypeptides. 
Alternatively, expression of FkpA-DsbC without a signal 
sequence may be employed in conjunction with Strains that 
have an oxidizing cytoplasm, such as the OrigamiTM E. coli 
strains marketed by Novagen/EMD Biosciences (Madison, 
Wis.). In this strain background, protein disulfides are formed 
in cytoplasmic proteins and the artificial disulfide isomerase 
proteins disclosed herein allow an increase in the yield of the 
correctly folded and biologically active polypeptide. 
EXAMPLES 
The following examples are included to further illustrate 
various aspects of the invention. It should be appreciated by 
those of skill in the art that the techniques disclosed in the 
examples that follow represent techniques and/or composi 
tions discovered by the inventor to function well in the prac 
tice of the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in the 
art should, in light of the present disclosure, appreciate that 
many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
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Example 1 
de novo Design of Disulfide Isomerase 
20 
protein with cis/trans peptidyl-prolyl isomerase activity in 
which each monomer is formed by an N-terminal dimeriza 
tion domain and a C-terminal catalytic domain, joined by a 
long C-helical linker. The two structural domains have been 
A study was undertaken for the denovo design of a protein 5 demonstrated to be stable on their own, and to function inde 
- pendently (Saul et al., 2004). In particular, the dimerization able to assist the folding of multidisulfide containing proteins - 0 domain exhibits chaperone activity and it has been reported to when overexpressed in the periplasm of E. coli. Engineered to - form a binding pocket for the interaction with the substrate contain no amino acid homology with the main bacterial - Y - - (Ramm and Pluckthun, 2001). A series of artificial enzymes protein disulfide isomerase DsbC, the rational design of this 10 were constructed, comprising the minimal FkpA N-terminal enzyme sought to recapitulate the essential features for bac- - 
- - - - domain that has been shown to exhibit chaperone activity terial disulfide isomerization. Previously, in fact, a number of - 0 - which includes a long C-helical liker at the C-terminus (Saul complementary strategies for elucidating the molecular fea- t al., 2004), fused to the DsbA molecule (FIG. 1 
tures of DsbC function have been investigated. In particular, el al., ), fused to the DsbA molecule (FIG. 1). 
it was hypothesized that the molecular requirements for a 15 Example 2 
protein that can catalyze isomerization of non-native disul 
fides in vivo are: (i) the presence of a peptide binding cleft Construction of FkpA-DsbC Chimera Proteins 
with chaperone activity, and (ii) the presence of two catalytic 
domains with a thioredoxin fold. In addition, the overall Bacterial strains and plasmids used in this study are listed 
molecular topology of disulfide 1somerases must depend on in Table 1. The genes encoding FkpA-DsbA chimeric pro 
(iii) the relative orientation of the active sites, which is in turn teins were constructed by overlap extension PCR (e.g., Aiyar 
influenced by the nature of the C-helical linker connecting the et al., 1996: U.S. Pat. No. 5,023,171) using the primers listed 
thioredoxin domain to the rest of molecule (Segatori et al., in Table 2 (SEQ ID NOs: 16-45), digested with Xbal and 
2004). HindIII and cloned into pBAD33 (Guzman, et al., 1995). All 
Artificial enzymes were designed to resemble the gross is the chimeras contained a C-terminal hexahistidine tag. For 
topology of DsbC, i.e., a V-shaped homodimeric molecule protein purification purposes the gene fusions were digested 
that contains a region for the binding with the Substrate with Xbaland HindIII, ligated into pET28a (Novagen, Madi 
between the arms of the V. FkpA is a homodimeric V-shaped son Wis.) and transformed into E. coli BL21 (DE3) cells. 
TABLE 1. 
Relevant Genotype Source 
Strains 
DHSa F-(f30dlacz-MI5)-(lac/ZY A-argF) U 169 deoR recA I Laboratory Collection 
endAlhsdR17(rk-, mk+)SupE44, thi-1 gyra 96, re/Al 
DHB4 arad139 (araA-feu)7679 (codB-fac)X74 gaE15 gaK16 Laboratory Collection 
rpsL150 re. Althi phoA (Pvull) phoR maF3 Flac+ (lad) pro 
MC1OOO arad139 (araA-feu) 7679 (cod8-lac)X74 01E15 ga Kl 6 Casadaban, 1980 
rpsL 150 ref Althi Flac+ (lac?) pro 
LM106 MC1000 disbA::kan5 Laboratory Collection 
LM102 MC1000 disbB::kanS Masip, 2004 
PB351 SFIOODdegP:kan DsbC Bessette, 2001 
PB401 SFIOODdegP:kan DsbA Bessette, 2001 
BL21 (DE3) FompT dcm (DE3) Laboratory Collection 
MB7O6 DHB4 DsbC, disbA:kan Beckwith laboratory 
Plasmid 
pET-28(a) T7 expression vector, C-terminal 6x histidine tag Nowagen 
bBADdsbC dsbC from Escherichia coil in pBAD33 Laboratory Collection 
bBADdsbA dsbA from Escherichia coil in pBAD34 Laboratory Collection 
TrcSt IvtPA tPA(46-175) with Still leader in pTrc99A oly, 1997 
pBAD-FkpADsbA1 FkpA(1-114) fused to DsbA.(1-189) in pBAD33 This work 
pBAD-FkpADsbA2 FkpA(1-114) fused to DsbA.(2-189) in pBAD33 This work 
pBAD-FkpADsbA3 FkpA(1-114) fused to DsbA(3-189) in pBAD33 This work 
pBAD-FkpADsbA4 FkpA(1-114) fused to DsbA(4-189) in pBAD33 This work 
pBAD-FkpADsbA5 FkpA(1-114) fused to DsbA(5-189) in pBAD33 This work 
pET28-FkpADsbA2 FkpA(1-114) fused to DsbA(2-189) in pET28 This work 
pET28-FkpADsbA3 FkpA(1-114) fused to DsbA(3-189) in pET28 This work 
pET28-FkpADsbA4 FkpA(1-114) fused to DsbA(4-189) in pET28 This work 
pET28-FkpADsbA5 FkpA(1-114) fused to DsbA(5-189) in pET28 This work 
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The FkpA polypeptide is a homodimeric V-shaped mol 
ecule with overall structural architecture (gross topology) 
similar to DsbC. Each monomer is composed of an N-termi 
nal dimerization domain (residues 1-114; FIG. 1: SEQ ID 
NO:2) and a C-terminal catalytic domain (residues 115-224) 
(FIG. 1). Residues 70-114 form a long C-helical linker that 
joins the two independent domains in each monomer. A series 
of fusions were constructed, encoding the dimerization 
domain, specifically residues 1-114 (SEQID NO:2) of FkpA 
fused to the 1, 2", 3", 4", or 5' residue of mature DsbA 
(SEQ ID NO:3), termed DsbA(1-189); DsbA(2-189), DsbA 
(3-189), DsbA(4-189), and DsbA(5-189), along with a hexa 
histidine tag, respectively, generating the respective mol 
ecules FkpA-DsbA1 (SEQID NO:4), FkpA-DsbA2 (SEQID 
NO:5), FkpA-DsbA3 (SEQ ID NO:6), FkpA-DsbA4 (SEQ 
ID NO:7), and FkpA-DsbA5 (SEQID NO:8). Differences in 
the nature of the amino acid region joining the two structur 
ally independent domains are presumed to result in different 
orientations of the portion of the chimera protein at the C-ter 
minal of the helical linker, i.e., the catalytic active sites. 
Furthermore, it has been reported that the relative orientation 
of the active sites in the thioredoxin domains is crucial to the 
catalytic function of the molecule (Segatoriet al., 2004). The 
fkpA-dsbA gene fusions were placed downstream from the 
arabinose promoter in the medium copy number plasmid 
pBAD33 (Guzman et al. 1995). Following induction of pro 
tein expression with arabinose, the wild-type DsbC and all the 
FkpA-DsbA chimeras accumulated to nearly identical levels, 
as determined by Western blotting with a polyclonal antibody 
that recognizes the C-terminal His tag. 
Example 3 
In vivo Disulfide Bond Formation and Isomerization 
To determine the effect of the FkpA-DsbA chimera con 
structs on the folding yield of a truncated version of the 
human tissue plasminogen containing 9 disulfide bonds, 
(vtPA, comprising the catalytic and kringle 2 domains of the 
full length protein), E. coli DHB4 (aralD139 (ara A-leu)7679 
(codB-lac)X74 galE 15 galK16 rpsL150 relA1 thi phoA 
(PvulI) phoR malF3 Flac"(lacI) prol) and E. coli PB401 
(SF100 AdegP::kan, dsbA::kan) were co-transformed with 
pBAD33 derivatives encoding the chimera genes, and with 
pTrcStIIvtPA, a pTrc99 derivative encoding the VtPA gene 
fused to the stII leader peptide (Bessette et al., 1999). Cultures 
were grown at 30°C. in 15 ml of LB medium with 50 ug/ml 
of amplicillin and 25 ug/ml of chloramphenicol. Cells were 
diluted 1:100 from overnight cultures, grown to ODoo of 0.8, 
and arabinose was added to a final concentration of 0.2%; 30 
min later, VtpA synthesis was induced with 1 mM isopropyl 
B-D-thiogalactopyranoside (IPTG). Following growth for 
three additional hours, 6 ml aliquots were pelleted by cen 
trifugation and stored at -20° C. The pellets were resus 
pended in cold PBS as needed to normalize the number of 
cells per sample, and lysed with a French press. Insoluble 
material was removed by centrifugation (12,000xg, 10 minat 
4°C.), and the soluble protein concentration was determined 
by the Bio-Rad protein assay. tea activities were obtained by 
first diluting the samples in 50 mM Tris-HCl (pH 7.4) with 
0.01% Tween 80 to a final protein concentration of 0.5 lug/ul. 
30 ul of the diluted cell lysates were added to 250 ul of the 
same buffer containing 0.04 ugful of human Glu-type plas 
minogen (American Diagnostica, Greenwich, Conn.), and 
0.4 mM Spectrozyme PL (American Diagnostica), incubated 
at 37°C., and the change in Aaos was monitored. To study the 













LM106 (MC1000 dsbA::kan5) and LM102 (MC1000 dsbB:: 
kan5) were transformed with the appropriate pBAD33 plas 
mid derivatives. Overnight cultures were grown in LB 
medium with 50 ug/ml of kanamycin and 25 g/ml of 
chloramphenicol, and diluted 1:100 in low phosphate mini 
mal medium containing MOPS salts, 0.2% glycerol, 0.2% 
glucose, 0.2% casein amino acids, and 0.5 g/ml thiamine, 
with 50 ug/ml of kanamycin and 25 ug/ml of chlorampheni 
col. When the cell density reached ODoo-0.4, arabinose was 
added to a final concentration of 0.2% w/v. Four hours later, 
cells were collected and mixed with 0.4 Miodoacetamide and 
lysis buffer (B-PERTM, Pierce) in a 1:2 ratio. The activity of 
alkaline phosphatase was determined as described previously 
(Brickmann and Beckwith, 1975). 
To determine the ability of the FkpA-DsbA chimera to 
complement the activity of DsbC and DsbA in medium 
supplemented with CuCl2, E. coli MB706 (araD139 (araA 
leu)7679 (codB-lac)X74 galE15 galK16 rpsL150 relA1 thi 
phoA (PvulI) phoR malF3 Flac"(lacI) pro AdsbC, dsbA:: 
kan) was transformed with p3AD33 derivatives encoding the 
chimera genes and plated on brain and heart infusion (BHI) 
medium (1.5% agar). Cultures were grown at 37°C. in BHI 
medium Supplemented with 50 ug/ml of amplicillin, 25 g/ml 
of chloramphenicol, and 50 ug/ml of kanamycin. Cells were 
diluted 1:100 from O/N cultures in BHI medium, grown for 
two hours under the same conditions, and the ODoo was 
measured. 100 ul of each culture, appropriately diluted to 
normalize the number of cells per sample (to ODoo 5*10 
cfu), were plated on BHI medium 1.5% agar, 0.2% arabinose, 
and supplemented with different CuCl2 concentration, rang 
ing from 0 to 12 mM, and antibiotics as described above. 
Plates were incubated at 37° C. for 18-22 hours. 
In vivo studies revealed that the FkpA-DsbA chimeras 
constructed are able to catalyze the rearrangement of non 
native disulfide bonds. Three of the enzymes, namely FkpA 
fused to the DsbA molecule starting from the 2',3', and 4' 
amino acid residues, were able to assist the folding of vtPA in 
the periplasm of E. coli to degrees comparable to the yield of 
active vtPA obtained overexpressing wild-type DsbC (FIG. 
2A). Thus the constructed artificial enzymes are disulfide 
isomerases in vivo. Moreover, the ability of these artificial 
enzymes to act as isomerases was dependent on the presence 
of DsbD, demonstrating that their catalytic domains are able 
to interact with DsbD and depend on it for their recycling. 
Although DsbD is able to reduce the monomeric DsbA 
extremely slowly in vitro (Rozhkova et al., 2004), the steric 
interactions created by dimerization of DsbA allow for the 
reduction of the artificial disulfide isomerases by DsbD in 
vivo. From gel filtration analysis of the purified proteins, it 
was observed that all the artificial disulfide isomerases are 
present exclusively as dimers. Because the in vivo folding of 
active vtPA was analyzed in an E. coli strain where DsbC is 
expressed in the periplasm from the chromosomal gene, the 
possibility that heterodimeric molecules generated by inter 
action between the dimerization domains of a wild-type 
DsbC monomerandofan FkpA-DsbA monomer has not been 
ruled out. However, the probability of this scenario is 
unlikely, in that the formation of such heterodimers would not 
significantly increase the yield of active vtPA with respect to 
the yield obtained in the background strain, in which the 
amount of periplasmic DsbC derives only from the chromo 
Somal copy of the gene. In addition, the same study was 
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performed in an overexpressing mutant of the FkpA-DsbA3 
enzyme (with DsbC as a control), where the N-terminal cys 
teine in the CXXC active site was substituted with analanine, 
to inactivate the oxidoreductase activity of the molecule. This 
substitution completely impaired the enzymes’ ability to 
assist the in vivo folding of vtPA, thus the possibility that the 
high chaperone activity of FkpA is responsible for the folding 
of VtPA can be ruled out. 
The ability of the artificial disulfide isomerases to simul 
taneously catalyze oxidase activity and rearrangement of 
non-native disulfides in vivo (i.e., assist the folding of vtPA in 
a dsbA background) was observed to be strictly correlated 
with their ability to complement for the lack of DsbA, and 
restore alkaline phosphatase activity. In other words, we 
showed that the catalysis of disulfide bond formation during 
the folding of vtPA indsbA cells overexpressing the FkpA 
DsbA chimeras could be attributed to their in vivo oxidase 
activity, in a DsbB-dependent fashion. For instance the arti 
ficial disulfide isomerase that displays the highest oxidase 
activity, FkpA-DsbA3, was also shown to assist the folding of 
vtPA in a disbA background strain (FIG. 2A). This suggests 
that the particular nature of the linkerjoining the two domains 
in each monomer influences the orientation of the active sites 
allowing for the reduction by DsbD and oxidation by DsbB in 
the periplasm of the same cell. Likewise, the moderate degree 
of isomerase activity exhibited by FkpA-DsbA2 and FkpA 
DsbA4 in a disbA-background (FIG. 2A) is presumably due 
to the limited ability of these enzymes to be oxidized by DsbB 
(FIG. 2B). The nature of the C-helical linker may affect the 
orientation of the catalytic domains, and the propensity of the 
molecule to be oxidized by DsbB. As a result, since the degree 
of in vivo oxidation is correlated to the amount of protein 
found in the oxidized State in the periplasmic space, the 
ability of the enzymes to catalyze the folding of VtPA in a 
dsbA strain is dependent on their oxidase activity. 
Strain Relevant Genotype 
DHB4 
DHB4 disbA- disbC 
DHB4 dsbA- dsbC-, pBAD33-fkpAdsbA1 
DHB4 dsbA- dsbC-, pBAD33-fkpAdsbA2 
DHB4 dsbA- dsbC-, pBAD33-fkpAdsbA3 
DHB4 dsbA- dsbC-, pBAD33-fkpAdsbA4 
DHB4 dsbA- dsbC-, pBAD33-fkpAdsbA5 
DHB4 disbA- dsbC-, pBAD33-dsbC 









Expression, Purification, and in vitro Biochemical 
Assays of FkpA-DsbA Chimera Proteins 
For the purification of the FkpA-DsbA chimera proteins, 
the appropriate genes were cloned behind the T7 promoter in 
pET28(a), and the resulting plasmids were transformed into 
E. coli BL21 (DE3). Protein expression and purification was 
performed as previously described (Segatorietal., 2004). The 
FkpA-DsbA2, FkpA-DsbA3, FkpA-DsbA4, and FkpA 
DsbA5 chimeras, and DsbC as a control were purified by 
IMAC chromatography and their oligomerization status was 
analyzed by gel filtration FPLC. All the proteins eluted exclu 
sively as dimers (e.g., FIG. 3). All proteins used in this study 
were more than 95% pure as judged by Coomassie Brilliant 
Blue-stained SDS-PAGEgels. 
The rate of insulin reduction in the presence of DTT was 
determined as previously described (Holmgren 1979). The 
change of Aso in the reaction was monitored as a direct 
measure of the aggregation of reduced insulin, and the activ 
ity is expressed as the ratio of the initial slope of the turbidity 
curve to the lag time (Martinez-Galisteo et al., 1995). The 
renaturation of reduced, denatured RNase A was determined 
as described by Lyles and Gilbert (Lyles and Gilbert, 1991). 
The protection of citrate synthase from thermal inactivation 
was monitored according to Buchner et al., 1998. The rate of 
thermal inactivation obtained with or without 0.4 uM of puri 
fied enzymes was determined. 
Lack of DsbC has been reported to cause sensitivity to 
copper in E. coli (Hiniker et al., 2005). As shown in table 3, a 
dsbA-dsbC E. colimutant strain lacking DsbC fails to grow in 
the presence of 24 mM CuCl2. However, the presence of a 
chimeric FkpADsbA protein allowed growth in the presence 
of 5-8 mM CuC1. 
TABLE 3 
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The intrinsic isomerase activity of the artificial disulfide 
isomerases was determined using RNase A as a substrate 
(Lyles and Gilbert, 1991). Interestingly, the artificial enzymes 
displayed low in vitro isomerase activity which was only 
15-21% of that of DsbC (Table 4). 
TABLE 4 
In vitro activities of purified enzymes 
RNAse Insulin 
Refolding Reduction* 
Enzyme |M/min/LM Enzyme * 10 D46so/min CS to(min) 
O.94 OO1 
DsbC OO67 0.012 5.81 - 0.21 3.15 O.OS 
FkpA-DsbA2 O.O12 O.OO1 O45 0.11 2.46 O.04 
FkpA-DsbA3 O.O13 O.OO1 O43 - 0.13 2.01 - O.OS 
FkpA-DsbA4 O.O14 O.OO3 O55 0.12 382 OO6 
FkpA-DsbA5 O.O1 O.OO1 O38 0.16 2.71 O.O7 
25 
This Suggests that the artificial disulfide isomerases, simi 
larly to the DsbC-DsbA chimeras (Segatori et al., 2004), 
might catalyze the rearrangement of non-native disulfides by 
cycles of reduction and oxidation of the substrate, rather than 
by mere catalysis of isomerization. As shown in FIG. 2B, 
FkpA-DsbA1 completely resists the oxidation by DsbB, and 
is therefore most likely present in the periplasm in a com 
pletely reduced State. In agreement with the conclusion Sug 
gested above, the yield of active vtPA observed when FkpA 
DsbA1 is overexpressed in the periplasm of a dsbA" bacterial 
strain is only slightly higher than the value obtained for the 
background strain. Likewise, FkpA-DsbA5 moderate oxi 
dase activity is consistent with its limited isomerase activity 
in vivo. Finally, without wishing to be bound by any theory, 
the higher propensity of FkpA-DsbA2, FkpA-DsbA3, and 
FkpA-DsbA4 to be oxidized by DsbB suggests that the frac 
tion of these enzymes present in the oxidized state is sufficient 
to catalyze the folding of VtPA in a disbA' strain through 
cycles of reduction and oxidation. However, in disbA cells, 
the artificial disulfide isomerases need to catalyze both oxi 
dation and rearrangement of disulfides. In this setting, the 
timing of oxidation and reduction cycles becomes more strin 
gent, and, without being bound by any theory, it is proposed 
that the steric hindrance generated by the specific orientation 
of the catalytic domains in the FkpA-DsbA2 and FkpA 
DsbA4 molecules (as opposed to FkpA-DsbA3) delays the 
interaction with the substrate, or the recycling by DsbB and 
DsbD, resulting in Sub-optimal timing of in vivo folding. 
The in vitro insulin reduction activity (Zhao et al., 2003) of 
the FkpA-DsbA chimeras was 7-10% of that of DsbC (Table 
4). For comparison, DsbA has about 10% of the activity of 
DsbC in this assay (Segatori et al., 2004). All the chimeras 
exhibited low disulfide isomerase activity in the refolding of 
reduced RNAse A. FkpA-DsbA2, FkpA-DsbA3, FkpA 
DsbA4, and FkpA-DsbA5, and DsbCdCN-TrXA displayed 
from 15 to 21% of the isomerase activity of DsbC, which in 
turn was 8-fold less active than protein disulfide-isomerase 
(PDI; EC 5.3.4.1). Without wishing to be bound by theory, 
one explanation is that because the C-helical linker in the 
FkpA-DsbA molecules is considerably longer than that of 










the overall three-dimensional structure of the artificial 
enzymes, and, as a result, in vitro, they act on the specific 
Substrate used in this assay, insulin, as two monomeric DsbA. 
This suggests that the reduction of insulin may not be an 
accurate measure of the reductase activity on the periplasm. 
Citrate Synthase 
Inactivation 







Similarly to what was observed in the refolding of RNAse A, 
the reduction of insulin is a measurement of the enzymes 
reductase activity per se, which therefore does not consider 
the outcome of possible in vivo interactions. 
Analysis of the artificial molecules in vitro chaperone 
activity was performed using citrate synthase as a Substrate, 
and monitoring the ability of the artificial enzymes to prevent 
the inactivation of citrate synthase by thermal denaturation 
(Table 4). The chaperone activity of all of the artificial disul 
fide bond isomerases was found to be comparable to that of 
DsbC. The half-life of denaturated CS is used as an indication 
of the enzyme chaperone activity. At a 2.7 fold stoichiometric 
excess, the half-life of CS incubated with FkpA-DsbA2, 
FkpA-DsbA3, FkpA-DsbA4, and FkpA-DsbA5 was 
observed to be respectively 0.8, 0.6, 1.2, and 0.9-fold the 
value obtained using DsbC as a chaperone (Table 4). 
Example 5 
Complementation of DsbA Activity by FkpA-DsbA 
Chimera Molecules 
The catalytic domain of the FkpA-DsbA chimera polypep 
tides is represented by the DsbA portion of the polypeptide. 
This raises the possibility that these molecules could simul 
taneously catalyze the oxidation and the rearrangement of 
non-native disulfide bonds indsbA cells, lacking DsbA. The 
folding of vtPA, in addition to requiring the overexpression of 
DsbC, is also dependent on the presence of a protein oxidant, 
namely DsbA. Therefore, in strain SF 100 (Baneyx and Geor 
giou, 1990) lacking DsbA, only background levels of active 
vtPA are observed. Multicopy expression of DsbC, in this 
strain background, also failed to yield active vtPA, since 
DsbC cannot serve as an efficient protein oxidant (FIG. 2A). 
In contrast, it was found that expression of one of the artificial 
disulfide isomerases, FkpA-DsbA3, afforded the same yield 
of active vtPA in cells with or without DsbA. The level of 
vtPA activity in this case was 13-fold higher than in disbA 
cells without plasmid. Thus, activity of this hybrid isomerase 
variant was not affected by the absence of DsbA. The other 
FkpA-DsbA chimeras showed weak vtPA folding activity in 
dsbA cells (FIG. 2A). 
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To verify that the ability of the chimeras to assist the 
folding of VtPA in a disbA background depends on these 
molecules oxidase activity, their ability to complement the 
phenotypes caused by the absence of DsbA was examined. In 
particular, dsbA mutant strains display very low alkaline 
phosphatase (PhoA) activity. Similarly to DsbC, FkpA 
DsbA1 which did not give vtPA activity above background in 
a disbA host was also not able to catalyze the formation of 
enzymatically active PhoA in MC4100 dsbA cells (FIG. 2B). 
However, the other four FkpA-DsbA variants were able to 
Support protein oxidation to various degrees. In E. coli 
MC1000 dsbA grown in low phosphate media, the PhoA 
activity is 30-fold lower than in its isogenic parent. Co-ex 
pression of FkpA-DsbA2, FkpA-DsbA3, FkpA-DsbA4, and 
FkpA-DsbA5 restored PhoA activity to respectively 43, 67. 
35, and 28% of the value obtained in the parental strain 
MC1000 (FIG. 2B). None of the FkpA-DsbA chimeras could 
restore PhoA activity indsbB cells (FIG. 2B), suggesting that 
the oxidase activity observed indsbA cells is dependent on 
the oxidation of the FkpA-DsbA chimeras by DsbB. 
All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be appar 
ent to those of skill in the art that variations may be applied to 
the compositions and methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
More specifically, it will be apparent that certain agents which 
are both chemically and physiologically related may be Sub 
stituted for the agents described herein while the same or 
similar results would beachieved. All such similar substitutes 
and modifications apparent to those skilled in the art are 
deemed to be within the spirit, scope and concept of the 
invention as defined by the appended claims. 
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<16O is NUMBER OF SEO ID NOS: 
<210s, SEQ ID NO 1 
&211s LENGTH: 270 
212. TYPE: PRT 
<213> ORGANISM: Escherichia 
<4 OOs, SEQUENCE: 1 
Met Lys Ser Leu Phe Llys Val 
1. 5 
Ala Lieu. His Ala Pro Ile Thr 
2O 
Thir Ala Ala Asp Ser Lys Ala 
35 
Ala Tyr Ala Lieu. Gly Ala Ser 
SO 55 
Lys Glu Glin Glu Lys Lieu. Gly 
65 70 
Ala Gly Val Glin Asp Ala Phe 
85 
Glu Ile Glu Glin. Thir Leul Glin 
1OO 
Ala Glin Ala Lys Met Glu Lys 
115 
Lys Glu Tyr Arg Glu Lys Phe 
13 O 135 
Ser Thr Gly Lieu Val Tyr Glin 
145 150 
Pro Lys Asp Ser Asp Thr Val 
1.65 
Asp Gly Lys Glu Phe Asp Asn 
18O 
Phe Arg Lieu. Asp Gly Val Ile 
195 
Ile Llys Lys Gly Gly Lys Ile 
21 O 215 
Tyr Gly Lys Ala Gly Val Pro 
225 23 O 
Phe Asp Val Glu Lieu. Lieu. Asp 
245 
Llys Pro Glu Ala Asp Ala Lys 
26 O 
<210s, SEQ ID NO 2 
&211s LENGTH: 114 
212. TYPE: PRT 
<213> ORGANISM: Escherichia 
<4 OOs, SEQUENCE: 2 
Met Lys Lys Gly Phe Met Leu 
1. 5 
Phe Ala Glin Ala Glin Llys Ser 
2O 
Arg Tyr Met Glu Asn. Ser Lieu 
35 














































































































Lieu. Lieu. Ala Ala Phe 
Ala Lieu. Gly Ala Ser 
3 O 






























Lieu. Asp Lys Asp Glin Lieu. Ile Ala Gly Val 
SO 55 
Llys Ser Lys Lieu. Ser Asp Glin Glu Ile Glu 
65 70 
Glu Ala Arg Val Llys Ser Ser Ala Glin Ala 
85 90 
Ala Asp Asn. Glu Ala Lys Gly Lys Glu Tyr 
1OO 105 
Glu Lys 
<210s, SEQ ID NO 3 
&211s LENGTH: 189 
212. TYPE: PRT 
<213> ORGANISM: Escherichia coli 
<4 OOs, SEQUENCE: 3 
Ala Glin Tyr Glu Asp Gly Lys Glin Tyr Thr 
1. 5 1O 
Ala Gly Ala Pro Glin Val Lieu. Glu Phe Phe 
2O 25 





35 4 O 
eu Pro Glu Gly Val Lys Met Thr Lys 
SO 55 
ly Asp Lieu. Gly Lys Asp Lieu. Thr Glin 
70 
eu Gly Val Glu Asp Llys Val Thr Val 
85 90 








sn Ala Gly Ile Llys Gly Glu Glu Tyr 
115 12 O 
all Val Lys Ser Lieu Val Ala Glin Glin 
3 O 135 
ln Leu Arg Gly Val Pro Ala Met Phe 
150 
Sn Pro Glin Gly Met Asp Thr Ser Asn 
1.65 17O 
Glin Tyr Ala Asp Thr Val Llys Tyr Lieu. Ser 
18O 185 
SEQ ID NO 4 
LENGTH: 309 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of 
Peptide 
SEQUENCE: 4 
Met Lys Lys Gly Phe Met Leu Phe Thr Lieu 
1. 
Phe Ala Glin Ala Glin Llys Ser Ala Tyr Ala 
2O 25 
Arg Tyr Met Glu Asn. Ser Lieu Lys Glu Glin 
























































Lieu. Ala Ala 


















































sp Lys Asp Glin Lieu. Ile Ala Gly Val 
SO 55 





la Arg Val Llys Ser Ser Ala Glin Ala 
85 90 
sp Asn. Glu Ala Lys Gly Lys Glu Tyr 
1OO 105 
Glu Lys Ala Glin Tyr Glu Asp Gly Lys Glin 
115 12 O 




3 O 135 
is Cys Tyr Glin Phe Glu Glu Val Lieu 
150 






et Gly Gly Asp Lieu. Gly Lys Asp Lieu 
18O 185 
et Ala Lieu. Gly Val Glu Asp Llys Val 
195 2OO 
al Glin Llys Thr Glin Thr Ile Arg Ser 
10 215 




er Phe Val Val Llys Ser Lieu Val Ala 
245 250 






26 O 265 
ln Lieu. Asn Pro Glin Gly Met Asp Thr 
27s 28O 
ln Glin Tyr Ala Asp Thr Val Llys Tyr 
9 O 295 
s His His His 
SEO ID NO 5 
LENGTH: 3O8 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of 
Peptide 
SEQUENCE: 5 
Met Lys Lys Gly Phe Met Leu Phe Thr Lieu 
1. 
Phe Ala Glin Ala Glin Llys Ser Ala Tyr Ala 
2O 25 
Arg Tyr Met Glu Asn. Ser Lieu Lys Glu Glin 
35 4 O 




er Lys Lieu. Ser Asp Glin Glu Ile Glu 
70 
Glu Ala Arg Val Llys Ser Ser Ala Glin Ala 
85 90 
US 7,829,687 B2 
- Continued 
Glin Asp Ala Phe Ala 
60 
Glin. Thir Lieu. Glin Ala 
7s 
Llys Met Glu Lys Asp 
95 
Arg Glu Lys Phe Ala 
11 O 
Tyr Thr Thr Lieu. Glu 
125 
Phe Phe Ser Phe Phe 
14 O 
His Ile Ser Asp Asn 
155 
Thr Lys Tyr His Val 
17s 
Thr Glin Ala Trp Ala 
19 O 
Thir Wall Pro Leu Phe 
2O5 
Ala Ser Asp Ile Arg 
22O 
Glu Tyr Asp Ala Ala 
235 
Glin Glin Glu Lys Ala 
255 
Met Phe Val Asn Gly 
27 O 
Ser Asn Met Asp Val 
285 
Lieu. Ser Glu Lys Llys 
3 OO 
Artificial Sequence: 
Lieu. Ala Ala Phe Ser 
15 
Lieu. Gly Ala Ser Lieu. 
3 O 
Glu Lys Lieu. Gly Ile 
45 
Glin Asp Ala Phe Ala 
60 
Glin. Thir Lieu. Glin Ala 
7s 











































































































































SEQ ID NO 6 
LENGTH: 
TYPE : 
ORGANISM: Artificial Sequence 
FEATURE: 
































































































































































































































































































































































































SEO ID NO 7 
LENGTH: 
TYPE : 
ORGANISM: Artificial Sequence 
FEATURE: 














































































































































































































































































US 7,829,687 B2 
41 
- Continued 
Gly Asp Lieu. Gly Lys Asp Lieu. Thr Glin Ala Trp Ala Val Ala Met Ala 
18O 185 19 O 
Lieu. Gly Val Glu Asp Llys Val Thr Val Pro Lieu. Phe Glu Gly Val Glin 
195 2OO 2O5 
Llys Thr Glin Thir Ile Arg Ser Ala Ser Asp Ile Arg Asp Val Phe Ile 
21 O 215 22O 
Asn Ala Gly Ile Lys Gly Glu Glu Tyr Asp Ala Ala Trp Asn. Ser Phe 
225 23 O 235 24 O 
Val Val Lys Ser Lieu Val Ala Glin Glin Glu Lys Ala Ala Ala Asp Wall 
245 250 255 
Glin Lieu. Arg Gly Val Pro Ala Met Phe Val Asn Gly Llys Tyr Glin Lieu. 
26 O 265 27 O 
Asn Pro Glin Gly Met Asp Thir Ser Asn Met Asp Val Phe Val Glin Glin 
27s 28O 285 
Tyr Ala Asp Thr Val Llys Tyr Lieu. Ser Glu Lys Llys His His His His 
29 O 295 3 OO 
His His 
3. OS 
<210s, SEQ ID NO 8 
&211s LENGTH: 305 
212. TYPE: PRT 
<213> ORGANISM: Escherichia coli 
<4 OOs, SEQUENCE: 8 
Met Lys Lys Gly Phe Met Leu Phe Thr Lieu. Leu Ala Ala Phe Ser Gly 
1. 5 1O 15 
Phe Ala Glin Ala Glin Llys Ser Ala Tyr Ala Lieu. Gly Ala Ser Lieu. Gly 
2O 25 3 O 
Arg Tyr Met Glu Asn. Ser Lieu Lys Glu Glin Glu Lys Lieu. Gly Ile Llys 
35 4 O 45 
Lieu. Asp Lys Asp Glin Lieu. Ile Ala Gly Val Glin Asp Ala Phe Ala Asp 
SO 55 60 
Llys Ser Lys Lieu. Ser Asp Glin Glu Ile Glu Gln Thr Lieu. Glin Ala Phe 
65 70 7s 8O 
Glu Ala Arg Val Llys Ser Ser Ala Glin Ala Lys Met Glu Lys Asp Ala 
85 90 95 
Ala Asp Asn. Glu Ala Lys Gly Lys Glu Tyr Arg Glu Lys Phe Ala Lys 
1OO 105 11 O 
Glu Lys Asp Gly Lys Glin Tyr Thir Thr Lieu. Glu Lys Pro Wall Ala Gly 
115 12 O 125 
Ala Pro Glin Val Lieu. Glu Phe Phe Ser Phe Phe Cys Pro His Cys Tyr 
13 O 135 14 O 
Glin Phe Glu Glu Val Lieu. His Ile Ser Asp Asn Val Llys Llys Llys Lieu. 
145 150 155 160 
Pro Glu Gly Val Lys Met Thr Lys Tyr His Val Asn Phe Met Gly Gly 
1.65 17O 17s 
Asp Lieu. Gly Lys Asp Lieu. Thr Glin Ala Trp Ala Val Ala Met Ala Lieu 
18O 185 19 O 
Gly Val Glu Asp Llys Val Thr Val Pro Lieu. Phe Glu Gly Val Glin Lys 
195 2OO 2O5 
Thr Glin Thir Ile Arg Ser Ala Ser Asp Ile Arg Asp Val Phe Ile Asn 
21 O 215 22O 
Ala Gly Ile Lys Gly Glu Glu Tyr Asp Ala Ala Trp Asn. Ser Phe Val 
225 23 O 235 24 O 
Val Lys Ser 
Lieu. Arg Gly 
Pro Glin Gly 
27s 




<210s, SEQ I 
43 
Lieu Wall Ala Glin Glin 
245 
Wall Pro Ala Met Phe 
26 O 
Met Asp Thr Ser Asn 
Val Llys Tyr Lieu. Ser 
D NO 9 
<4 OOs, SEQUENCE: 9 
OOO 
<210s, SEQ I D NO 10 
<4 OOs, SEQUENCE: 10 
OOO 
<210s, SEQ I 
&211s LENGT 
212. TYPE : 
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- Continued 




Val Asn Gly Llys Tyr Glin Lieu. Asn 
265 27 O 
Met Asp Val Phe Val Glin Glin Tyr 
285 
Glu Lys Llys His His His 
3 OO 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATU 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
RE: 

















<210s, SEQ I 
&211s LENGT 
















a CCaCCaC ca. 

















ttagcggcgt titt Caggctt 
Ctggg.tc.gtt acatggaaaa 
aaagat cagc tigatcgctgg 
Caagagat.cg alacagactict 
aagatggaaa aagacgcggc 
gcc aaagaga aag.cgcagta 
gaagaagttctgcatatttic 





ggtaaat atc agctgaatcc 
Cagtatgctg. atacagtgaa 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATU 




tgcticaggct 6 O 
Ctectictaaaa. 12 O 
tgttcaggat 18O 
acaag catt c 24 O 
tgataacgaa 3OO 
tgaagatggit 360 
ggagtttitt C 42O 
tgataatgtg 48O 
Catgggtggit 54 O 
cgtggaagac 6OO 
ttctgcttct 660 
cgcgg.cgtgg 72 O 
tgacgtgcaa. 78O 
gCaggg tatg 84 O 
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- Continued 
CaCCaCCaCC accactaa 918 
SEQ ID NO 16 
LENGTH: 59 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
SEQUENCE: 16 
gagotcgaat t ct ctagatt aaagaggaga aaggt accca tatgaagaa aggttitt at 59 
SEO ID NO 17 
LENGTH: 28 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
SEQUENCE: 17 
atgaagaaag gttittatgtt gtt tactt 28 
SEQ ID NO 18 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
SEQUENCE: 18 
aagcctgaaa acgc.cgctaa caaagtaaac aacataaaac citt 43 
SEQ ID NO 19 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
SEQUENCE: 19 
gttagcggcg ttitt Caggct ttgct caggc tigctgaagct gca 43 
SEQ ID NO 2 O 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
SEQUENCE: 2O 
tgtcagcagc tigtagcaggt tttgcagctt cagcagoctg agc 43 
SEQ ID NO 21 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
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- Continued 
alacctgctac agctgctgac agcaaagcag cqttcaaaaa ta 
<210s, SEQ ID NO 22 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 22 
tgcataagct gatttctgat cqt catttitt gaacgctgct ttg 
<210s, SEQ ID NO 23 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 23 
gatcagaaat cagctitatgc actgggtgcc ticgctgggtc gtt 
<210s, SEQ ID NO 24 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 24 
tcttittagag agttitt coat gtaacgaccc agc gaggcac cca 
<210s, SEQ ID NO 25 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 25 
catggaaaac tot ctaaaag aacaagaaaa actgggcatc aaa 
<210s, SEQ ID NO 26 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 26 
cgat cagotg atctittatcc agtttgatgc ccagtttitt c ttg 
<210s, SEQ ID NO 27 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 27 
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SEQ ID NO 28 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
SEQUENCE: 28 
gtcggaga.gt ttgct cittat cagcaaatgc atcctgaaca cca 
SEQ ID NO 29 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
SEQUENCE: 29 
gatalaga.gca aactict Coga C caagagatc galacagactic tac 
SEQ ID NO 3 O 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
SEQUENCE: 3 O 
ttcacgcgag citt cqaatgc titgtagagt c tdttcgatct citt 
SEQ ID NO 31 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
SEQUENCE: 31 
agcattcaa gct cqcgtga agt cttctgc ticaggcgaag atg 
SEQ ID NO 32 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
SEQUENCE: 32 
cgittat cago cqcgtc.ttitt to catctt cq cct gagcaga aga 
SEQ ID NO 33 
LENGTH: 43 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
SEQUENCE: 33 
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<210s, SEQ ID NO 34 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 34 
tittct ctittg gcaaatttct cqcgg tactic tittaccttitt gct 
<210s, SEQ ID NO 35 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 35 
ctgtttacca tott catact gcgctttct c tittggcaaat titc 
<210s, SEQ ID NO 36 
&211s LENGTH: 48 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
< 4 OO > SEQUENCE: 36 
gtag togtact gtttaccatc tt catact.gt ttct ctittgg caaatttic 
<210s, SEQ ID NO 37 
&211s LENGTH: 49 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OO > SEQUENCE: 37 
caggg tagtg tactgtttac catctt cata titt ct ctittg gcaaattitc 
<210s, SEQ ID NO 38 
&211s LENGTH: 46 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 38 
caggg tagtg tactgtttac catcttctitt citctittggca aatttic 
<210s, SEQ ID NO 39 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 39 
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<210s, SEQ ID NO 4 O 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 4 O 
gaaatttgcc aaa.gagaaag cqcagtatga agatggtaaa Cag 
<210s, SEQ ID NO 41 
&211s LENGTH: 48 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 41 
gaaatttgcc aaa.gagaaac agtatgaaga tigg taalacag tacactac 
<210s, SEQ ID NO 42 
&211s LENGTH: 49 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 42 
gaaatttgcc aaa.gagaaat atgaagatgg taalacagtac act accctg 
<210s, SEQ ID NO 43 
&211s LENGTH: 46 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 43 
gaaatttgcc aaa.gagaaag aagatggtaa acagtacact accctg 
<210s, SEQ ID NO 44 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 44 
gaaatttgcc aaa.gagaaag atggtaaa.ca gtacact acc Ctg 
<210s, SEQ ID NO 45 
&211s LENGTH: 54 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<4 OOs, SEQUENCE: 45 
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What is claimed is: 
1. An isolated nucleic acid molecule encoding a chimeric 
polypeptide comprising: 
a) a first DNA segment encoding a FkpA polypeptide, 
wherein the FkpA polypeptide allows for dimerization 
and provides a Substrate binding region; and 
b) a second DNA segment encoding a DsbA polypeptide; 
wherein the first and second DNA segments are linked 5' to 3'; 
and wherein the chimeric polypeptide comprises one or more 
activities selected from the group consisting of disulfide 
bond reduction activity, disulfide bond oxidation activity, 
disulfide bond isomerization activity, and chaperone activity. 
2. The isolated nucleic acid molecule of claim 1, wherein 
the first DNA segment has from about 80% to about 99% 
sequence identity with SEQID NO:1. 
3. The isolated nucleic acid molecule of claim 2, wherein 
the first DNA segment encodes a polypeptide comprising 
SEQID NO:2. 
4. The isolated nucleic acid molecule of claim 1, wherein 
the second DNA segment encodes a polypeptide comprising 
SEQID NO:3. 
5. The isolated nucleic acid molecule of claim 1, wherein 
the chimeric polypeptide comprises a sequence selected from 
the group consisting of SEQIDNO:4, SEQID NO:5, SEQID 
NO:6, SEQID NO:7, and SEQID NO:8. 
6. An expression construct comprising the nucleic acid 
molecule of claim 1 and a DNA segment encoding a polypep 
tide comprising at least two disulfide bonds. 
7. An isolated host cell comprising the nucleic acid mol 
ecule of claim 1. 
8. The host cell of claim 7, wherein the host cell is a gram 
negative or a gram positive bacterial cell. 
9. The host cell of claim 7, wherein the host cell is an 
Escherichia coli cell. 
10. The host cell of claim 7, wherein the host cell expresses 








11. A method for producing a biologically active heterolo 
gous polypeptide in a host cell comprising: 
a) culturing isolated host cells in a culture medium, 
wherein the host cells comprise both the nucleic acid 
molecule of claim 1 and a second nucleic acid molecule 
that encodes a heterologous polypeptide which com 
prises at least two disulfide bonds in its native form: 
b) expressing the nucleic acid molecule of claim 1 and the 
second nucleic acid molecule in the host cells under 
conditions effective to produce said chimeric polypep 
tide, and said heterologous polypeptide and; 
c) isolating the heterologous polypeptide. 
12. The method of claim 11, wherein the heterologous 
polypeptide is selected from the group consisting of human 
tPA; vtPA, RNAse A, and PhoA. 
13. The method of claim 11, wherein the host cells are 
bacterial cells. 
14. The method of claim 13, wherein the bacterial cells 
express DsbD and DsbB. 
15. The method of claim 13, wherein the bacterial cells are 
gram-negative bacterial cells. 
16. The method of claim 15, wherein the bacterial cells are 
E. coli cells. 
17. The method of claim 11, wherein the heterologous 
polypeptide is operatively linked to a signal sequence that 
functions to cause secretion of the polypeptide from the host 
cell cytoplasm. 
18. The method of claim 17, wherein the signal sequence 
comprises Omp.A, Lpp, LamB, MalE, PelB, or StII. 
19. The method of claim 11, wherein the nucleic acid 
molecule of claim 1 and the second nucleic acid molecule are 
both expressed by a single host cell. 
20. The method of claim 11, wherein the nucleic acid 
molecule of claim 1 and the second nucleic acid molecule are 
expressed by separate host cells. 
21. The method of claim 11, wherein the heterologous 
polypeptide is isolated from the culture medium of the host 
cells. 
